<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">04801</article-id><article-id pub-id-type="doi">10.7554/eLife.04801</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>Mitochondrial Ca<sup>2+</sup> uptake by the voltage-dependent anion channel 2 regulates cardiac rhythmicity</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-19114"><name><surname>Shimizu</surname><given-names>Hirohito</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-19115"><name><surname>Schredelseker</surname><given-names>Johann</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-19116"><name><surname>Huang</surname><given-names>Jie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-19117"><name><surname>Lu</surname><given-names>Kui</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="fn" rid="pa2">¶</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19118"><name><surname>Naghdi</surname><given-names>Shamim</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19119"><name><surname>Lu</surname><given-names>Fei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19120"><name><surname>Franklin</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="pa3">§</xref><xref ref-type="other" rid="par-10"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19121"><name><surname>Fiji</surname><given-names>Hannah DG</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19122"><name><surname>Wang</surname><given-names>Kevin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19123"><name><surname>Zhu</surname><given-names>Huanqi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19124"><name><surname>Tian</surname><given-names>Cheng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19125"><name><surname>Lin</surname><given-names>Billy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19126"><name><surname>Nakano</surname><given-names>Haruko</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-23870"><name><surname>Ehrlich</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19127"><name><surname>Nakai</surname><given-names>Junichi</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19128"><name><surname>Stieg</surname><given-names>Adam Z</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7312-9364</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19129"><name><surname>Gimzewski</surname><given-names>James K</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19130"><name><surname>Nakano</surname><given-names>Atsushi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19131"><name><surname>Goldhaber</surname><given-names>Joshua I</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="par-11"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19132"><name><surname>Vondriska</surname><given-names>Thomas M</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19133"><name><surname>Hajnóczky</surname><given-names>György</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-12"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19134"><name><surname>Kwon</surname><given-names>Ohyun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-18951"><name><surname>Chen</surname><given-names>Jau-Nian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Molecular, Cell and Developmental Biology</institution>, <institution>University of California, Los Angeles</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Chemistry and Biochemistry</institution>, <institution>University of California, Los Angeles</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">MitoCare Center, Department of Pathology, Anatomy and Cell Biology</institution>, <institution>Thomas Jefferson University</institution>, <addr-line><named-content content-type="city">Philadelphia</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Anesthesiology</institution>, <institution>University of California, Los Angeles</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Broad Center of Regenerative Medicine and Stem Cell Research</institution>, <institution>University of California, Los Angeles</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><label>6</label><institution content-type="dept">Brain Science Institute</institution>, <institution>Saitama University</institution>, <addr-line><named-content content-type="city">Saitama</named-content></addr-line>, <country>Japan</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">California NanoSystems Institute</institution>, <institution>University of California, Los Angeles</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">WPI Center for Materials Nanoarchitectonics</institution>, <institution>National Institute for Materials Science</institution>, <addr-line><named-content content-type="city">Tsukuba</named-content></addr-line>, <country>Japan</country></aff><aff id="aff9"><label>9</label><institution content-type="dept">School of Physics, Centre for Nanoscience and Quantum Information</institution>, <institution>University of Bristol</institution>, <addr-line><named-content content-type="city">Bristol</named-content></addr-line>, <country>UK</country></aff><aff id="aff10"><label>10</label><institution>Cedars-Sinai Heart Institute</institution>, <addr-line><named-content content-type="city">Los Angeles</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nunnari</surname><given-names>Jodi</given-names></name><role>Reviewing editor</role><aff><institution>University of California, Davis</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>chenjn@mcdb.ucla.edu</email></corresp><fn fn-type="con" id="equal-contrib"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Walther-Straub Institute for Pharmacology and Toxicology, Ludwig-Maximilians University, Munich, Germany</p></fn><fn fn-type="present-address" id="pa2"><label>¶</label><p>College of Bioengineering, Tianjin University of Science and Technology, Tianjin, China</p></fn><fn fn-type="present-address" id="pa3"><label>§</label><p>Department of Internal Medicine, Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, United States</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>01</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>4</volume><elocation-id>e04801</elocation-id><history><date date-type="received"><day>17</day><month>09</month><year>2014</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>© 2014, Shimizu et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Shimizu et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-04801-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.04801.001</object-id><p>Tightly regulated Ca<sup>2+</sup> homeostasis is a prerequisite for proper cardiac function. To dissect the regulatory network of cardiac Ca<sup>2+</sup> handling, we performed a chemical suppressor screen on zebrafish <italic>tremblor</italic> embryos, which suffer from Ca<sup>2+</sup> extrusion defects. Efsevin was identified based on its potent activity to restore coordinated contractions in <italic>tremblor</italic>. We show that efsevin binds to VDAC2, potentiates mitochondrial Ca<sup>2+</sup> uptake and accelerates the transfer of Ca<sup>2+</sup> from intracellular stores into mitochondria. In cardiomyocytes, efsevin restricts the temporal and spatial boundaries of Ca<sup>2+</sup> sparks and thereby inhibits Ca<sup>2+</sup> overload-induced erratic Ca<sup>2+</sup> waves and irregular contractions. We further show that overexpression of VDAC2 recapitulates the suppressive effect of efsevin on <italic>tremblor</italic> embryos whereas VDAC2 deficiency attenuates efsevin's rescue effect and that VDAC2 functions synergistically with MCU to suppress cardiac fibrillation in <italic>tremblor</italic>. Together, these findings demonstrate a critical modulatory role for VDAC2-dependent mitochondrial Ca<sup>2+</sup> uptake in the regulation of cardiac rhythmicity.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.001">http://dx.doi.org/10.7554/eLife.04801.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.04801.002</object-id><title>eLife digest</title><p>The heart is a large muscle that pumps blood around the body by maintaining a regular rhythm of contraction and relaxation. If the heart loses this regular rhythm it works less efficiently, which can lead to life-threatening conditions.</p><p>Regular heart rhythms are maintained by changes in the concentration of calcium ions in the cytoplasm of the heart muscle cells. These changes are synchronised so that the heart cells contract in a controlled manner. In each cell, a contraction begins when calcium ions from outside the cell enter the cytoplasm by passing through a channel protein in the membrane that surrounds the cell. This triggers the release of even more calcium ions into the cytoplasm from stores within the cell. For the cells to relax, the calcium ions must then be pumped out of the cytoplasm to lower the calcium ion concentration back to the original level.</p><p>Shimizu et al. studied a zebrafish mutant—called <italic>tremblor</italic>—that has irregular heart rhythms because its heart muscle cells are unable to efficiently remove calcium ions from the cytoplasm. Embryos of the <italic>tremblor</italic> mutant were treated with a wide variety of chemical compounds with the aim of finding some that could correct the heart defect.</p><p>A compound called efsevin restores regular heart rhythms in <italic>tremblor</italic> mutants. Efsevin binds to a pump protein called VDAC2, which is found in compartments called mitochondria within the cell. Although mitochondria are best known for their role in supplying energy for the cell, they also act as internal stores for calcium. By binding to VDAC2, efsevin increases the rate at which calcium ions are pumped from the cytoplasm into the mitochondria. This restores rhythmic calcium ion cycling in the cytoplasm and enables the heart muscle cells to develop regular rhythms of contraction and relaxation. Increasing the levels of VDAC2 or another similar calcium ion pump protein in the heart cells can also restore a regular heart rhythm.</p><p>Efsevin can also correct irregular heart rhythms in human and mouse heart muscle cells, therefore the new role for mitochondria in controlling heart rhythms found by Shimizu et al. appears to be shared in other animals. The experiments have also identified the VDAC family of proteins as potential new targets for drug therapies to treat people with irregular heart rhythms.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.002">http://dx.doi.org/10.7554/eLife.04801.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>mitochondria</kwd><kwd>arrhythmia</kwd><kwd>calcium handling</kwd><kwd>heart</kwd><kwd>VDAC</kwd><kwd>fibrillation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL081700 and HL096980</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Jau-Nian</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM071779 and P41GM081282</award-id><principal-award-recipient><name><surname>Kwon</surname><given-names>Ohyun</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>The Nakajima Foundation</institution></institution-wrap></funding-source><award-id>Graduate Student Fellowship</award-id><principal-award-recipient><name><surname>Shimizu</surname><given-names>Hirohito</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004543</institution-id><institution>China Scholarship Council</institution></institution-wrap></funding-source><award-id>Graduate Student Fellowship</award-id><principal-award-recipient><name><surname>Lu</surname><given-names>Fei</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007185</institution-id><institution>University of California, Los Angeles</institution></institution-wrap></funding-source><award-id>Philip Whitcome Training Program, Graduate Student Fellowship</award-id><principal-award-recipient><name><surname>Lu</surname><given-names>Fei</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Laubisch Foundation</institution></institution-wrap></funding-source><award-id>Faculty Award</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Jau-Nian</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>Erwin-Schrodinger Stipendium Postdoctoral Fellowship</award-id><principal-award-recipient><name><surname>Schredelseker</surname><given-names>Johann</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007185</institution-id><institution>University of California, Los Angeles</institution></institution-wrap></funding-source><award-id>Broad Stem Cell Research Center Faculty Award</award-id><principal-award-recipient><name><surname>Nakano</surname><given-names>Atsushi</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL105699</award-id><principal-award-recipient><name><surname>Vondriska</surname><given-names>Thomas M</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL107674</award-id><principal-award-recipient><name><surname>Franklin</surname><given-names>Sarah</given-names></name></principal-award-recipient></award-group><award-group id="par-11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL070828</award-id><principal-award-recipient><name><surname>Goldhaber</surname><given-names>Joshua I</given-names></name></principal-award-recipient></award-group><award-group id="par-12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM059419</award-id><principal-award-recipient><name><surname>Hajnóczky</surname><given-names>György</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Enhancing mitochondrial Ca<sup>2+</sup> uptake effectively suppresses aberrant Ca<sup>2+</sup> induced arrhythmogenic events in zebrafish, mouse and human cardiomyocytes, demonstrating a critical role for mitochondria in the regulation of cardiac rhythmicity.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>During development, well-orchestrated cellular processes guide cells from diverse lineages to integrate into the primitive heart tube and establish rhythmic and coordinated contractions. While many genes and pathways important for cardiac morphogenesis have been identified, molecular mechanisms governing embryonic cardiac rhythmicity are poorly understood. The findings that Ca<sup>2+</sup> waves traveling across the heart soon after the formation of the primitive heart tube (<xref ref-type="bibr" rid="bib11">Chi et al., 2008</xref>) and that loss of function of key Ca<sup>2+</sup> regulatory proteins, such as the L-type Ca<sup>2+</sup> channel, Na/K−ATPase and sodium-calcium exchanger 1 (NCX1), severely impairs normal cardiac function (<xref ref-type="bibr" rid="bib47">Rottbauer et al., 2001</xref>; <xref ref-type="bibr" rid="bib54">Shu et al., 2003</xref>; <xref ref-type="bibr" rid="bib22">Ebert et al., 2005</xref>; <xref ref-type="bibr" rid="bib35">Langenbacher et al., 2005</xref>), indicate an essential role for Ca<sup>2+</sup> handling in the regulation of embryonic cardiac function.</p><p>Ca<sup>2+</sup> homoeostasis in cardiac muscle cells is tightly regulated at the temporal and spatial level by a subcellular network involving multiple proteins, pathways, and organelles. The release and reuptake of Ca<sup>2+</sup> by the sarcoplasmic reticulum (SR), the largest Ca<sup>2+</sup> store in cardiomyocytes, constitutes the primary mechanism governing the contraction and relaxation of the heart. Ca<sup>2+</sup> influx after activation of the L-type Ca<sup>2+</sup> channel in the plasma membrane induces the release of Ca<sup>2+</sup> from the SR via ryanodine receptor (RyR) channels, which leads to an increase of the intracellular Ca<sup>2+</sup> concentration and cardiac contraction. During diastolic relaxation, Ca<sup>2+</sup> is transferred back into the SR by the SR Ca<sup>2+</sup> pump or extruded from the cell through NCX1. Defects in cardiac Ca<sup>2+</sup> handling and Ca<sup>2+</sup> overload, for example during cardiac ischemia/reperfusion or in long QT syndrome, are well known causes of contractile dysfunction and many types of arrhythmias including early and delayed afterdepolarizations and Torsade des pointes (<xref ref-type="bibr" rid="bib4">Bers, 2002</xref>; <xref ref-type="bibr" rid="bib12">Choi et al., 2002</xref>; <xref ref-type="bibr" rid="bib57">Yano et al., 2008</xref>; <xref ref-type="bibr" rid="bib28">Greiser et al., 2011</xref>).</p><p>Ca<sup>2+</sup> crosstalk between mitochondria and ER/SR has been noted in many cell types and the voltage-dependent anion channel (VDAC) and the mitochondrial Ca<sup>2+</sup> uniporter (MCU) serve as primary routes for Ca<sup>2+</sup> entry through the outer and inner mitochondrial membranes, respectively (<xref ref-type="bibr" rid="bib44">Rapizzi et al., 2002</xref>; <xref ref-type="bibr" rid="bib2">Bathori et al., 2006</xref>; <xref ref-type="bibr" rid="bib53">Shoshan-Barmatz et al., 2010</xref>; <xref ref-type="bibr" rid="bib3">Baughman et al., 2011</xref>; <xref ref-type="bibr" rid="bib18">De Stefani et al., 2011</xref>). In the heart, mitochondria are tethered to the SR and are located in close proximity to Ca<sup>2+</sup> release sites (<xref ref-type="bibr" rid="bib26">García-Pérez et al., 2008</xref>; <xref ref-type="bibr" rid="bib6">Boncompagni et al., 2009</xref>; <xref ref-type="bibr" rid="bib30">Hayashi et al., 2009</xref>). This subcellular architecture exposes the mitochondria near the Ca<sup>2+</sup> release sites to a high local Ca<sup>2+</sup> concentration that is sufficient to overcome the low Ca<sup>2+</sup> affinity of MCU and facilitates Ca<sup>2+</sup> crosstalk between SR and mitochondria (<xref ref-type="bibr" rid="bib26">García-Pérez et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Dorn and Scorrano, 2010</xref>; <xref ref-type="bibr" rid="bib33">Kohlhaas and Maack, 2013</xref>). Increase of the mitochondrial Ca<sup>2+</sup> concentration enhances energy production during higher workload and dysregulation of SR-mitochondrial Ca<sup>2+</sup> signaling results in energetic deficits and oxidative stress in the heart and may trigger programmed cell death (<xref ref-type="bibr" rid="bib7">Brandes and Bers, 1997</xref>; <xref ref-type="bibr" rid="bib37">Maack et al., 2006</xref>; <xref ref-type="bibr" rid="bib33">Kohlhaas and Maack, 2013</xref>). However, whether SR-mitochondrial Ca<sup>2+</sup> crosstalk also contributes significantly to cardiac Ca<sup>2+</sup> signaling during excitation-contraction coupling requires further investigation.</p><p>In zebrafish, the <italic>tremblor</italic> (<italic>tre</italic>) locus encodes a cardiac-specific isoform of the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger 1, NCX1h (also known as slc8a1a) (<xref ref-type="bibr" rid="bib22">Ebert et al., 2005</xref>; <xref ref-type="bibr" rid="bib35">Langenbacher et al., 2005</xref>). The <italic>tre</italic> mutant hearts lack rhythmic Ca<sup>2+</sup> transients and display chaotic Ca<sup>2+</sup> signals in the myocardium leading to unsynchronized contractions resembling cardiac fibrillation (<xref ref-type="bibr" rid="bib35">Langenbacher et al., 2005</xref>). In this study, we used <italic>tre</italic> as an animal model for aberrant Ca<sup>2+</sup> handling-induced cardiac dysfunction and took a chemical genetic approach to dissect the Ca<sup>2+</sup> regulatory network important for maintaining cardiac rhythmicity. A synthetic compound named efsevin was identified from a suppressor screen due to its potent ability to restore coordinated contractions in <italic>tre</italic>. Using biochemical and genetic approaches we show that efsevin interacts with VDAC2 and potentiates its mitochondrial Ca<sup>2+</sup> transporting activity and spatially and temporally modulates cytosolic Ca<sup>2+</sup> signals in cardiomyocytes. The important role of mitochondrial Ca<sup>2+</sup> uptake in regulating cardiac rhythmicity is further supported by the suppressive effect of VDAC2 and MCU overexpression on cardiac fibrillation in <italic>tre</italic>.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><sec id="s2-1"><title>Identification of a chemical suppressor of <italic>tre</italic> cardiac dysfunction</title><p>Homozygous <italic>tre</italic> mutant embryos suffer from Ca<sup>2+</sup> extrusion defects and manifest chaotic cardiac contractions resembling fibrillation (<xref ref-type="bibr" rid="bib22">Ebert et al., 2005</xref>; <xref ref-type="bibr" rid="bib35">Langenbacher et al., 2005</xref>). To dissect the regulatory network of Ca<sup>2+</sup> handling in cardiomyocytes and to identify mechanisms controlling embryonic cardiac rhythmicity, we screened the BioMol library and a collection of synthetic compounds for chemicals that are capable of restoring heartbeat either completely or partially in <italic>tre</italic> embryos. A dihydropyrrole carboxylic ester compound named efsevin was identified based on its ability to restore persistent and rhythmic cardiac contractions in <italic>tre</italic> mutant embryos in a dose-dependent manner (<xref ref-type="fig" rid="fig1">Figure 1A,E</xref>, and <xref ref-type="other" rid="media1 media2 media3 media4">Videos 1–4</xref>). To validate the effect of efsevin, we assessed cardiac performance of wild type, <italic>tre</italic> and efsevin-treated <italic>tre</italic> embryos (<xref ref-type="bibr" rid="bib41">Nguyen et al., 2009</xref>). Fractional shortening of efsevin treated <italic>tre</italic> mutant hearts was comparable to that of their wild type siblings and heart rate was restored to approximately 40% of that observed in controls (<xref ref-type="fig" rid="fig1">Figure 1B–D</xref>). Periodic local field potentials accompanying each heartbeat were detected in wild type and efsevin-treated <italic>tre</italic> embryos using a microelectrode array (<xref ref-type="fig" rid="fig1">Figure 1F–H</xref>). Furthermore, while only sporadic Ca<sup>2+</sup> signals were detected in <italic>tre</italic> hearts, in vivo Ca<sup>2+</sup> imaging revealed steady Ca<sup>2+</sup> waves propagating through efsevin-treated <italic>tre</italic> hearts (<xref ref-type="fig" rid="fig1">Figure 1I</xref>, <xref ref-type="other" rid="media5 media6 media7">Videos 5–7</xref>), demonstrating that cardiomyocytes are functionally coupled and that efsevin treatment restores regular Ca<sup>2+</sup> transients in <italic>tre</italic> hearts.<fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.04801.003</object-id><label>Figure 1.</label><caption><title>Efsevin restores rhythmic cardiac contractions in zebrafish tremblor embryos.</title><p>(<bold>A</bold>) Line scans across the atria of <italic>Tg(myl7:GFP)</italic> embryonic hearts at 48 hpf. Rhythmically alternating systoles and diastoles are recorded from vehicle- (upper left) or efsevin- treated wild type (upper right) and efsevin-treated <italic>tre</italic> (lower right) embryos, while only sporadic unsynchronized contractions are recorded from vehicle-treated <italic>tre</italic> embryos (lower left). (<bold>B</bold>, <bold>C</bold>) Fractional shortening (FS) deduced from the line-scan traces. While cardiac contraction was not observed in <italic>tre</italic>, efsevin-treated wild type and <italic>tre</italic> hearts have similar levels of FS to those observed in control hearts. Ventricular FS of wild type v.s. wild type + efsevin vs tre + efsevin: 39 ± 0.6%, n = 8 vs 39 ± 1%, n = 10 vs 35 ± 3%, n = 6; and Atrial FS: 37 ± 1%, n = 11 vs 35 ± 2%, n = 11 vs 33 ± 2%, n = 15. (<bold>D</bold>) While efsevin restored a heart rate of 46 ± 2 beats per minute (bpm) in <italic>tre</italic> embryos, same treatment does not affect the heart rate in wild type embryos (126 ± 2 bpm in vehicle-treated embryos vs 123 ± 3 bpm in efsevin-treated wild-type embryos). ***, p &lt; 0.001 by one-way ANOVA. (<bold>E</bold>) Dose-dependence curve for efsevin. The <italic>tre</italic> embryos were treated with various concentrations of efsevin from 24 hpf and cardiac contractions were analyzed at 48 hpf. (<bold>F</bold>–<bold>H</bold>) Representative time traces of local field potentials for wild type (<bold>F</bold>), <italic>tre</italic> (<bold>G</bold>) and efsevin-treated <italic>tre</italic> (<bold>H</bold>) embryos clearly display periods of regular, irregular, and restored periodic electrical activity. (<bold>I</bold>) In vivo optical maps of Ca<sup>2+</sup> activation represented by isochronal lines every 33 ms recorded from 36 hpf wild type (left), <italic>tre</italic> (center) and efsevin-treated <italic>tre</italic> (right) embryos.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.003">http://dx.doi.org/10.7554/eLife.04801.003</ext-link></p></caption><graphic xlink:href="elife-04801-fig1-v1.tif"/></fig><media content-type="glencoe play-in-place height-250 width-310" id="media1" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media1.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.004</object-id><label>Video 1.</label><caption><title>The video shows a heart of a wild-type zebrafish embryo at 2 dpf.</title><p>Robust rhythmic contractions can be observed in atrium and ventricle.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.004">http://dx.doi.org/10.7554/eLife.04801.004</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media2" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media2.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.005</object-id><label>Video 2.</label><caption><title>This video shows a heart of a <italic>tremblor</italic> embryo at 2 dpf.</title><p>Embryos of the mutant line <italic>tremblor</italic> display only local, unsynchronized contractions, comparable to cardiac fibrillation.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.005">http://dx.doi.org/10.7554/eLife.04801.005</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media3" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media3.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.006</object-id><label>Video 3.</label><caption><title>This video shows a heart of a <italic>tremblor</italic> embryo at 2 dpf treated with efsevin.</title><p>Treatment of <italic>tremblor</italic> embryos with efsevin restores rhythmic contractions with comparable atrial fractional shortening compared to wild-type embryos and approximately 40% of wild-type heart rate.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.006">http://dx.doi.org/10.7554/eLife.04801.006</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media4" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media4.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.007</object-id><label>Video 4.</label><caption><title>The video shows a heart of a wild-type zebrafish embryo at 2 dpf treated with efsevin.</title><p>Treatment of wild-type embryos with efsevin did not affect cardiac performance, indicated by robust, rhythmic contractions comparable to untreated wild-type embryos.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.007">http://dx.doi.org/10.7554/eLife.04801.007</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media5" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media5.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.008</object-id><label>Video 5.</label><caption><title>Heat map of Ca<sup>2+</sup> transients recorded in 1 day old wild type heart.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.008">http://dx.doi.org/10.7554/eLife.04801.008</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media6" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media6.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.009</object-id><label>Video 6.</label><caption><title>Heat map of Ca<sup>2+</sup> transients recorded in 1 day old <italic>tremblor</italic> heart.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.009">http://dx.doi.org/10.7554/eLife.04801.009</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media7" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media7.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.010</object-id><label>Video 7.</label><caption><title>Heat map of Ca<sup>2+</sup> transients recorded in 1 day old efsevin treated <italic>tremblor</italic> heart.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.010">http://dx.doi.org/10.7554/eLife.04801.010</ext-link></p></caption></media></p></sec><sec id="s2-2"><title>Efsevin suppresses Ca<sup>2+</sup> overload-induced irregular contraction</title><p>We next examined whether efsevin could suppress aberrant Ca<sup>2+</sup> homeostasis-induced arrhythmic responses in mammalian cardiomyocytes. Mouse embryonic stem cell-derived cardiomyocytes (mESC-CMs) establish a regular contraction pattern with rhythmic Ca<sup>2+</sup> transients (<xref ref-type="fig" rid="fig2">Figure 2A,B,E,F</xref>). Mimicking Ca<sup>2+</sup> overload by increasing extracellular Ca<sup>2+</sup> levels was sufficient to disrupt normal Ca<sup>2+</sup> cycling and induce irregular contractions in mESC-CMs (<xref ref-type="fig" rid="fig2">Figure 2C,E,F</xref>). Remarkably, efsevin treatment restored rhythmic Ca<sup>2+</sup> transients and cardiac contractions in these cells (<xref ref-type="fig" rid="fig2">Figure 2D–F</xref>). Similar effect was observed in human embryonic stem cell-derived cardiomyocytes (hESC-CMs) (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Together, these findings suggest that efsevin targets a conserved Ca<sup>2+</sup> regulatory mechanism critical for maintaining rhythmic cardiac contraction in fish, mice and humans.<fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.04801.011</object-id><label>Figure 2.</label><caption><title>Efsevin reduces arrhythmogenic events in ES cell-derived cardiomyocytes.</title><p>(<bold>A</bold>) Line-scan analysis of Ca<sup>2+</sup> transients in mESC-CMs after 10 days of differentiation. (<bold>B</bold>–<bold>D</bold>) Representative graph of Ca<sup>2+</sup> transients detected in mESC-CMs (<bold>B</bold>). After treatment with 10 mM Ca<sup>2+</sup> for 10 min, the EB showed an irregular pattern of Ca<sup>2+</sup> transients (<bold>C</bold>). Efsevin treatment restores regular Ca<sup>2+</sup> transients under Ca<sup>2+</sup> overload conditions in mESC-CMs (<bold>D</bold>). (<bold>E</bold>) Plotted intervals between peaks of Ca<sup>2+</sup> signals detected in mESC-CMs prior to treatment (control), in 10 mM Ca<sup>2+</sup><sub>ext</sub> (Ca<sup>2+</sup>) and in 10 mM Ca<sup>2+</sup><sub>ext</sub>+10 μM efsevin (Ca<sup>2+</sup>+efsevin). (<bold>F</bold>, <bold>G</bold>) Plotted intervals of contractions detected in EBs prior to treatment (control), in 10 mM Ca<sup>2+</sup><sub>ext</sub> (Ca<sup>2+</sup>) and in 10 mM Ca<sup>2+</sup><sub>ext</sub> + 10 μM efsevin (Ca<sup>2+</sup> + efsevin) for mouse ESC-CMs (<bold>F</bold>) and 5 mM Ca<sup>2+</sup><sub>ext</sub> (Ca<sup>2+</sup>) and in 5 mM Ca<sup>2+</sup><sub>ext</sub> + 5 μM efsevin (Ca<sup>2+</sup> + efsevin) for human ESC-CMs (<bold>G</bold>). ***, p &lt; 0.001 by F-test.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.011">http://dx.doi.org/10.7554/eLife.04801.011</ext-link></p></caption><graphic xlink:href="elife-04801-fig2-v1.tif"/></fig></p></sec><sec id="s2-3"><title>VDAC2 mediates the suppressive effect of efsevin on <italic>tre</italic></title><p>To identify the protein target of efsevin, we generated a N-Boc-protected 2-aminoethoxyethoxyethylamine linker-attached efsevin (efsevin<sup>L</sup>) (<xref ref-type="fig" rid="fig3">Figure 3A,C</xref>). This modified compound retained the activity of efsevin to restore cardiac contractions in <italic>ncx1h</italic> deficient embryos (<xref ref-type="fig" rid="fig3">Figure 3B,D</xref>) and was used to create efsevin-conjugated agarose beads (efsevin<sup>LB</sup>). A 32kD protein species was detected from zebrafish lysate due to its binding ability to efsevin<sup>LB</sup> and OK-C125<sup>LB</sup>, an active efsevin derivative conjugated to beads, but not to beads capped with ethanolamine alone or beads conjugated with an inactive efsevin analog (OK-C19<sup>LB</sup>) (<xref ref-type="fig" rid="fig3">Figure 3A–E</xref>). Furthermore, preincubation of zebrafish lysate with excess efsevin prevented the 32kD protein from binding to efsevin<sup>LB</sup> or OK-C125<sup>LB</sup> (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Mass spectrometry analysis revealed that this 32kD band represents a zebrafish homologue of the mitochondrial voltage-dependent anion channel 2 (VDAC2) (<xref ref-type="fig" rid="fig3">Figure 3F</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).<fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.04801.012</object-id><label>Figure 3.</label><caption><title>VDAC2 is a protein target of efsevin.</title><p>(<bold>A</bold>) Structures of efsevin and two derivatives, OK-C125 and OK-C19. (<bold>B</bold>) Efsevin and OK-C125 restored rhythmic contractions in the majority of <italic>tremblor</italic> embryos, whereas OK-C19 failed to rescue the <italic>tremblor</italic> phenotype. (<bold>C</bold>) Structures of linker-attached compounds (indicated by superscript L). (<bold>D</bold>) Compounds efsevin<sup>L</sup> and OK-C125<sup>L</sup> retained their ability to restore rhythmic contractions in NCX1hMO injected embryos, while the inactive derivative OK-C19<sup>L</sup> was still unable to induce rhythmic contraction. (<bold>E</bold>) Affinity agarose beads covalently linked with efsevin (efsevin<sup>LB</sup>) or OK-C125 (OK-C125<sup>LB</sup>) pulled down 2 protein species from zebrafish embryonic lysate, whereof one, the 32 kD upper band, was sensitive to competition with a 100-fold excess free efsevin<sup>L</sup>. The 32 kD band was not detected in proteins eluted from beads capped with ethanolamine alone (beads<sup>C</sup>) or beads linked to OK-C19 (OK-C19<sup>LB</sup>). Arrowheads point to the 32kD bands. (<bold>F</bold>) Mass Spectrometry identifies the 32kD band as VDAC2. Peptides identified by mass spectrometry (underlined) account for 30% of the total sequence.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.012">http://dx.doi.org/10.7554/eLife.04801.012</ext-link></p></caption><graphic xlink:href="elife-04801-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04801.013</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Mass Spectometry identifies VDAC2 as the target of efsevin.</title><p>Image shows an example of the identification of VDAC2 peptide. Diagnostic b- and y-series ions are shown in red and blue, respectively.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.013">http://dx.doi.org/10.7554/eLife.04801.013</ext-link></p></caption><graphic xlink:href="elife-04801-fig3-figsupp1-v1.tif"/></fig></fig-group></p><p>VDAC2 is expressed in the developing zebrafish heart (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), making it a good candidate for mediating efsevin’s effect on cardiac Ca<sup>2+</sup> handling. To examine this possibility, we injected in vitro synthesized VDAC2 RNA into <italic>tre</italic> embryos and found that the majority of these embryos had coordinated cardiac contractions similar to those subjected to efsevin treatment (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="other" rid="media8 media9 media10 media11">Videos 8–11</xref>). In addition, we generated <italic>myl7:VDAC2</italic> transgenic fish in which VDAC2 expression can be induced in the heart by tebufenozide (TBF) (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Knocking down NCX1h in <italic>myl7:VDAC2</italic> embryos results in chaotic cardiac movement similar to <italic>tre</italic>. Like efsevin treatment, induction of VDAC2 expression by TBF treatment restored coordinated and rhythmic contractions in <italic>myl7:VDAC2;NCX1h MO</italic> hearts (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="other" rid="media12 media13">Videos 12,13</xref>). Conversely, knocking down VDAC2 in <italic>tre</italic> hearts attenuated the suppressive effect of efsevin (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="other" rid="media14 media15 media16">Videos 14–16</xref>). Furthermore, we generated VDAC2 null embryos by the Zinc Finger Nuclease gene targeting approach (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Similar to that observed in morpholino knockdown embryos, homozygous <italic>VDAC2</italic><sup><italic>LA2256</italic></sup> embryos do not exhibit noticeable morphological defects, but the suppressive effect of efsevin was attenuated in homozygous <italic>VDAC2<sup>LA2256</sup>; NCX1MO</italic> embryos (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). These findings demonstrate that VDAC2 is a major mediator for efsevin’s effect on <italic>ncx1h</italic> deficient hearts.<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.04801.014</object-id><label>Figure 4.</label><caption><title>VDAC2 restores rhythmic cardiac contractions in <italic>tre</italic>.</title><p>(<bold>A</bold>) In situ hybridization analysis showed that VDAC2 is expressed in embryonic hearts at 36 hpf (upper image) and 48 hpf (lower image). (<bold>B</bold>) Injection of 25 pg in vitro synthesized VDAC2 mRNA restored cardiac contractions in 52.9 ± 12.1% (n = 78) of 1-day-old <italic>tre</italic> embryos, compared to 21.8 ± 5.1% in uninjected siblings (n = 111). (<bold>C</bold>) Schematic diagram of <italic>myl7:VDAC2</italic> construct (top). In situ hybridization analysis showed that TBF treatment induces VDAC2 expression in the heart (lower panel). (<bold>D</bold>) While only ∼20% of <italic>myl7:VDAC2;NCX1hMO</italic> embryos have coordinated contractions (n = 116), 52.3 ± 2.4% of these embryos established persistent, rhythmic contractions after TBF induction of VDAC2 (n = 154). (<bold>E</bold>) On average, 71.2 ± 8.8% efsevin treated embryos have coordinated cardiac contractions (n = 131). Morpholino antisense oligonucleotide knockdown of VDAC2 (MO<sup>VDAC2</sup>) attenuates the ability of efsevin to suppress cardiac fibrillation in <italic>tre</italic> embryos (45.3 ± 7.4% embryos with coordinated contractions, n = 94). (<bold>F</bold>) Efsevin treatment restores coordinated cardiac contractions in 76.2 ± 8.7% NCX1MO embryos, only 54.1 ± 3.6% VDAC2<sup>zfn/zfn</sup>;NCX1MO embryos have coordinated contractions (n = 250). (<bold>G</bold>) Diagram of Zinc finger target sites. <italic>VDAC2</italic><sup><italic>zfn/zfn</italic></sup> carries a 34 bp deletion in exon 3 which results in a premature stop codon (red asterisk). In situ hybridization analysis showing loss of VDAC2 transcripts in <italic>VDAC2</italic><sup><italic>zfn/zfn</italic></sup> embryos. White arrowheads point to the developing heart.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.014">http://dx.doi.org/10.7554/eLife.04801.014</ext-link></p></caption><graphic xlink:href="elife-04801-fig4-v1.tif"/></fig><media content-type="glencoe play-in-place height-250 width-310" id="media8" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media8.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.015</object-id><label>Video 8.</label><caption><title>This video shows a heart of a wild-type zebrafish embryo at 1 dpf.</title><p>Robust rhythmic contractions can be observed in atrium and ventricle.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.015">http://dx.doi.org/10.7554/eLife.04801.015</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media9" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media9.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.016</object-id><label>Video 9.</label><caption><title>This video shows a heart of a wild-type zebrafish embryo injected with zebrafish VDAC2 mRNA at 1 dpf.</title><p>Robust rhythmic contractions can be observed in atrium and ventricle.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.016">http://dx.doi.org/10.7554/eLife.04801.016</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media10" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media10.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.017</object-id><label>Video 10.</label><caption><title>This video shows a heart of a <italic>tremblor</italic> embryo at 1 dpf.</title><p><italic>Tremblor</italic> embryos display only local, unsynchronized contractions, comparable to cardiac fibrillation.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.017">http://dx.doi.org/10.7554/eLife.04801.017</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media11" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media11.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.018</object-id><label>Video 11.</label><caption><title>This video shows a heart of a <italic>tremblor</italic> embryo injected with zebrafish VDAC2 mRNA at 1 dpf.</title><p>Overexpression of zebrafish VDAC2 mRNA restores rhythmic contractions in <italic>tremblor</italic> embryos.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.018">http://dx.doi.org/10.7554/eLife.04801.018</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media12" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media12.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.019</object-id><label>Video 12.</label><caption><title>This video shows a heart of a 2 dpf Tg-VDAC2 embryo injected with a morpholino targeting NCX1h.</title><p>Morpholino knock-down of NCX1h results in a fibrillating heart.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.019">http://dx.doi.org/10.7554/eLife.04801.019</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media13" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media13.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.020</object-id><label>Video 13.</label><caption><title>This video shows a heart of a 2 dpf NCX1h morphant in the Tg-VDAC2 genetic background.</title><p>TBF treatment induces VDAC2 expression and restores coordinated cardiac contractions.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.020">http://dx.doi.org/10.7554/eLife.04801.020</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media14" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media14.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.021</object-id><label>Video 14.</label><caption><title>This video shows a heart of a 2 dpf wild type zebrafish embryo injected with a morpholino targeting VDAC2.</title><p>Morpholino knockdown of VDAC2 did not have obvious effects on cardiac performance.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.021">http://dx.doi.org/10.7554/eLife.04801.021</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media15" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media15.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.022</object-id><label>Video 15.</label><caption><title>This video shows a heart of a 2 dpf <italic>tremblor</italic> mutant embryo injected with a morpholino targeting VDAC2.</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.022">http://dx.doi.org/10.7554/eLife.04801.022</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media16" mime-subtype="mov" mimetype="video" xlink:href="elife-04801-media16.mov"><object-id pub-id-type="doi">10.7554/eLife.04801.023</object-id><label>Video 16.</label><caption><title>This video shows a heart of a 2 dpf <italic>tremblor</italic> mutant embryo injected with a morpholino targeting VDAC2.</title><p>Efsevin treatment cannot restore coordinated cardiac contractions in the absence of VDAC2.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.023">http://dx.doi.org/10.7554/eLife.04801.023</ext-link></p></caption></media></p></sec><sec id="s2-4"><title>VDAC2-dependent effect of efsevin on mitochondrial Ca<sup>2+</sup> uptake</title><p>VDAC is an abundant channel located on the outer mitochondrial membrane serving as a primary passageway for metabolites and ions (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) (<xref ref-type="bibr" rid="bib44">Rapizzi et al., 2002</xref>; <xref ref-type="bibr" rid="bib2">Bathori et al., 2006</xref>; <xref ref-type="bibr" rid="bib53">Shoshan-Barmatz et al., 2010</xref>). At its close state, VDAC favours Ca<sup>2+</sup> flux (<xref ref-type="bibr" rid="bib56">Tan and Colombini, 2007</xref>). To examine whether efsevin would modulate mitochondrial Ca<sup>2+</sup> uptake via VDAC2, we transfected HeLa cells with VDAC2. We noted increased mitochondrial Ca<sup>2+</sup> uptake in permeabilized VDAC2 transfected and efsevin-treated cells after the addition of Ca<sup>2+</sup> and the combined treatment further enhanced mitochondrial Ca<sup>2+</sup> levels (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).<fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.04801.024</object-id><label>Figure 5.</label><caption><title>Efsevin enhances mitochondrial Ca<sup>2+</sup> uptake.</title><p>(<bold>A</bold>) HeLa cells were transfected with a flag-tagged zebrafish VDAC2 (VDAC2<sup>flag</sup>), immunostained against the flag epitope and counterstained for mitochondria with MitoTracker Orange and for nuclei with DAPI. (<bold>B</bold>) Representative traces of mitochondrial matrix [Ca<sup>2+</sup>] ([Ca<sup>2+</sup>]<sub>m</sub>) detected by Rhod2. Arrows denote the addition of Ca<sup>2+</sup>. Mitochondrial Ca<sup>2+</sup> uptake was assessed when VDAC2 was overexpressed (left), cells were treated with 1 µM efsevin (middle) and combination of both at suboptimal doses (right). Control-traces with ruthenium red (RuRed) show mitochondrial specificity of the signal. (<bold>C</bold>) Representative traces of cytosolic [Ca<sup>2+</sup>] ([Ca<sup>2+</sup>]<sub>c</sub>) changes upon the application of 7.5 µM IP<sub>3</sub> in the presence (+) or absence (−) of RuRed. Mitochondrial Ca<sup>2+</sup> uptake was assessed by the difference of the – and + RuRed conditions normalized to the total release (n = 4; mean ± SE). (<bold>D</bold>) MEFs overexpressing zebrafish VDAC2 (polycistronic with mCherry) were stimulated with 1 μM ATP in a nominally Ca<sup>2+</sup> free buffer. Changes in [Ca<sup>2+</sup>]<sub>c</sub> and [Ca<sup>2+</sup>]<sub>m</sub> were imaged using fura2 and mitochondria-targeted inverse pericam, respectively. Black and gray traces show the [Ca<sup>2+</sup>]<sub>c</sub> (in nM) and [Ca<sup>2+</sup>]<sub>m</sub> (F<sub>0</sub>/F mtpericam) time courses in the absence (left) or present (right) of efsevin. (<bold>E</bold>) Bar charts: Cell population averages for the peak [Ca<sup>2+</sup>]<sub>c</sub> (left), the corresponding [Ca<sup>2+</sup>]<sub>m</sub> (middle), and the coupling time (time interval between the maximal [Ca<sup>2+</sup>]<sub>c</sub> and [Ca<sup>2+</sup>]<sub>m</sub> responses) in the presence (black, n = 24) or absence (gray, n = 28) of efsevin.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.024">http://dx.doi.org/10.7554/eLife.04801.024</ext-link></p></caption><graphic xlink:href="elife-04801-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04801.025</object-id><label>Figure 5—figure supplement 1.</label><caption><title>Local Ca<sup>2+</sup> delivery between IP3 receptors and VDAC2.</title><p>V1V3DKO MEFs were stimulated with 100 μM ATP (left) or 2 μM thapsigargan (Tg) (right). Changes in [Ca<sup>2+</sup>]<sub>c</sub> and [Ca<sup>2+</sup>]<sub>m</sub> were imaged using fura2 and mitochondria targeted inverse pericam, respectively. Representative traces obtained in three cells are shown.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.025">http://dx.doi.org/10.7554/eLife.04801.025</ext-link></p></caption><graphic xlink:href="elife-04801-fig5-figsupp1-v1.tif"/></fig></fig-group></p><p>Mitochondria are located in close proximity to Ca<sup>2+</sup> release sites of the ER/SR and an extensive crosstalk between the two organelles exists (<xref ref-type="bibr" rid="bib26">García-Pérez et al., 2008</xref>; <xref ref-type="bibr" rid="bib30">Hayashi et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Brown and O'Rourke, 2010</xref>; <xref ref-type="bibr" rid="bib20">Dorn and Scorrano, 2010</xref>; <xref ref-type="bibr" rid="bib33">Kohlhaas and Maack, 2013</xref>). We examined whether Ca<sup>2+</sup> released from intracellular stores could be locally transported into mitochondria through VDAC2 in VDAC1/VDAC3 double knockout (V1/V3DKO) MEFs where VDAC2 is the only VDAC isoform being expressed (<xref ref-type="bibr" rid="bib48">Roy et al., 2009a</xref>). While treatments with ATP, an IP3-linked agonist, and thapsigargin, a SERCA inhibitor, stimulated similar global cytoplasmic [Ca<sup>2+</sup>] elevation in intact cells, only ATP induced a rapid mitochondrial matrix [Ca<sup>2+</sup>] rise (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). This finding is consistent with observations obtained in other cell types (<xref ref-type="bibr" rid="bib46">Rizzuto et al., 1994</xref>; <xref ref-type="bibr" rid="bib29">Hajnóczky et al., 1995</xref>) and suggests that Ca<sup>2+</sup> was locally transferred from IP3 receptors to mitochondria through VDAC2 at the close ER-mitochondrial associations. We next investigated whether this process could be modulated by efsevin. In permeabilized V1/V3DKO MEFs, treatment with efsevin increased the amount of Ca<sup>2+</sup> transferred into mitochondria during IP<sub>3</sub>-induced Ca<sup>2+</sup> release (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Also, in intact V1/V3 DKO MEFs, efsevin accelerated the transfer of Ca<sup>2+</sup> released from intracellular stores into mitochondria during stimulation with ATP (<xref ref-type="fig" rid="fig5">Figure 5D,E</xref>).</p></sec><sec id="s2-5"><title>Efsevin modulates Ca<sup>2+</sup> sparks and suppresses erratic Ca<sup>2+</sup> waves in cardiomyocytes</title><p>We next examined the effect of efsevin on cytosolic Ca<sup>2+</sup> signals in isolated adult murine cardiomyocytes. We found that efsevin treatment induced faster inactivation kinetics without affecting the amplitude or time to peak of paced Ca<sup>2+</sup> transients (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Similarly, efsevin treatment did not significantly alter the frequency, amplitude or Ca<sup>2+</sup> release flux of spontaneous Ca<sup>2+</sup> sparks, local Ca<sup>2+</sup> release events, but accelerated the decay phase resulting in sparks with a shorter duration and a narrower width (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). These results indicate that by activating mitochondrial Ca<sup>2+</sup> uptake, efsevin accelerates Ca<sup>2+</sup> removal from the cytosol in cardiomyocytes and thereby restricts local cytosolic Ca<sup>2+</sup> sparks to a narrower domain for a shorter period of time without affecting SR Ca<sup>2+</sup> load or RyR Ca<sup>2+</sup> release. Under conditions of Ca<sup>2+</sup> overload, single Ca<sup>2+</sup> sparks can trigger opening of neighbouring Ca<sup>2+</sup> release units and thus induce the formation of erratic Ca<sup>2+</sup> waves (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Efsevin treatment significantly reduced the number of propagating Ca<sup>2+</sup> waves in a dosage-dependent manner (<xref ref-type="fig" rid="fig6">Figure 6C,D</xref>), demonstrating a potent suppressive effect of efsevin on the propagation of Ca<sup>2+</sup> overload-induced Ca<sup>2+</sup> waves and suggesting that efsevin could serve as a pharmacological tool to manipulate local Ca<sup>2+</sup> signals.<fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.04801.026</object-id><label>Figure 6.</label><caption><title>Effects of efsevin on isolated cardiomyocytes.</title><p>(<bold>A</bold>) Electrically paced Ca<sup>2+</sup> transients at 0.5 Hz (top). Normalized quantification of Ca<sup>2+</sup> transient parameters reveals no difference for transient amplitude (efsevin-treated at 98.6 ± 4.5% of vehicle-treated) and time to peak (95 ± 3.9%), but a significant decrease for the rate of decay (82.8 ± 4% of vehicle- for efsevin-treated) (lower panel). (<bold>B</bold>) Representation of typical Ca<sup>2+</sup> sparks of vehicle- and efsevin treated cardiomyocytes (top). No differences were observed for spark frequency (101.1 ± 7.7% for efsevin- compared to vehicle-treated), maximum spark amplitude (101.6 ± 2.5%) and Ca<sup>2+</sup> release flux (98.7 ± 2.8%). In contrast, the decay phase of the single spark was significantly faster in efsevin treated cells (82.5 ± 2.1% of vehicle-treated). Consequently, total duration of the spark was reduced to 85.7 ± 2% and the total width was reduced to 89.5 ± 1.4% of vehicle-treated cells. *, p &lt; 0.05; ***, p &lt; 0.001. (<bold>C</bold>) Increasing concentrations of extracellular Ca<sup>2+</sup> induced a higher frequency of spontaneous propagating Ca<sup>2+</sup> waves in isolated adult murine ventricular cardiomyocytes. Efsevin treatment reduced Ca<sup>2+</sup> waves in a dose-dependent manner. (<bold>D</bold>) Quantitative analysis of spontaneous Ca<sup>2+</sup> waves spanning more than half of the entire cell. Addition of 1 µM efsevin reduced Ca<sup>2+</sup> waves to approximately half. Increasing the concentration of efsevin to 10 µM further reduced the number of spontaneous Ca<sup>2+</sup> waves and 25 µM efsevin almost entirely blocked the formation of Ca<sup>2+</sup> waves.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.026">http://dx.doi.org/10.7554/eLife.04801.026</ext-link></p></caption><graphic xlink:href="elife-04801-fig6-v1.tif"/></fig></p></sec><sec id="s2-6"><title>Mitochondrial Ca<sup>2+</sup> uptake modulates embryonic cardiac rhythmicity</title><p>We hypothesize that efsevin treatment/VDAC2 overexpression suppresses aberrant Ca<sup>2+</sup> handling-associated arrhythmic cardiac contractions by buffering excess Ca<sup>2+</sup> into mitochondria. This hypothesis predicts that activating other mitochondrial Ca<sup>2+</sup> uptake molecules would likewise restore coordinated contractions in <italic>tre</italic>. To test this model, we cloned zebrafish MCU and MICU1, an inner mitochondrial membrane Ca<sup>2+</sup> transporter and its regulator (<xref ref-type="bibr" rid="bib42">Perocchi et al., 2010</xref>; <xref ref-type="bibr" rid="bib3">Baughman et al., 2011</xref>; <xref ref-type="bibr" rid="bib18">De Stefani et al., 2011</xref>; <xref ref-type="bibr" rid="bib38">Mallilankaraman et al., 2012</xref>; <xref ref-type="bibr" rid="bib15">Csordas et al., 2013</xref>). In situ hybridization showed that MCU and MICU1 were expressed in the developing zebrafish heart (<xref ref-type="fig" rid="fig7">Figure 7A</xref>) and their expression levels were comparable between the wild type and <italic>tre</italic> hearts (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Overexpression of MCU restored coordinated contractions in <italic>tre</italic>, akin to what was observed with VDAC2 (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). In addition, <italic>tre</italic> embryos injected with suboptimal concentrations of MCU or VDAC2 had a fibrillating heart, but embryos receiving both VDAC2 and MCU at the suboptimal concentration manifested coordinated contractions (<xref ref-type="fig" rid="fig7">Figure 7C</xref>), demonstrating a synergistic effect of these proteins. Furthermore, overexpression of MCU failed to suppress the <italic>tre</italic> phenotype in the absence of VDAC2 activity and VDAC2 could not restore coordinated contractions in <italic>tre</italic> without functional MCU (<xref ref-type="fig" rid="fig7">Figure 7B,D</xref>). Similar results were observed by manipulating MICU1 activity (<xref ref-type="fig" rid="fig7">Figure 7E,F</xref>). Together, these findings indicate that mitochondrial Ca<sup>2+</sup> uptake mechanisms on outer and inner mitochondrial membranes act cooperatively to regulate cardiac rhythmicity.<fig-group><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.04801.027</object-id><label>Figure 7.</label><caption><title>Mitochondria regulate cardiac rhythmicity through a VDAC2-dependent mechanism.</title><p>(<bold>A</bold>) MCU and MICU1 are expressed in the developing zebrafish hearts (arrowhead). (<bold>B</bold>) Overexpression of MCU is sufficient to restore coordinated cardiac contractions in <italic>tre</italic> embryos (47.1 ± 1.6% embryos, n = 112 as opposed to 18.3 ± 5.3% of uninjected siblings, n = 64) while this effect is significantly attenuated when co-injected with morpholino antisense oligonucleotide targeted to VDAC2 (27.1 ± 1.9% embryos, n = 135). (<bold>C</bold>) Suboptimal overexpression of MCU (MCU<sup>S</sup>) and VDAC2 (VDAC2<sup>S</sup>) in combination is able to suppress cardiac fibrillation in <italic>tre</italic> embryos (42.9 ± 2.6% embryos, n = 129). (<bold>D</bold>) The ability of VDAC2 to restore rhythmic contractions in <italic>tre</italic> embryos (48.5 ± 3.5% embryos, n = 111) is significantly attenuated when MCU is knocked down by antisense oligonucleotide (MO<sup>MCU</sup>) (25.6 ± 2.4% embryos, n = 115). (<bold>E</bold>) Overexpression of MICU1 is sufficient to restore rhythmic cardiac contractions in <italic>tre</italic> embryos (49.3 ± 3.4% embryos, n = 127 compared to 16.8 ± 1.4% of uninjected siblings, n = 150). This effect is abrogated by VDAC2 knockdown (MO<sup>VDAC2</sup>, 25.3 ± 5.5% embryos, n = 97). (<bold>F</bold>) Suboptimal overexpression of MICU1 (MICU1<sup>S</sup>) and VDAC2 (VDAC2<sup>S</sup>) in combination is able to restore rhythmic cardiac contractions in <italic>tre</italic> embryos (48.6 ± 6.0%, n = 106). Error bars represent s.d.; *p &lt; 0.05; ***p &lt; 0.001.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.027">http://dx.doi.org/10.7554/eLife.04801.027</ext-link></p></caption><graphic xlink:href="elife-04801-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.04801.028</object-id><label>Figure 7—figure supplement 1.</label><caption><title>Expression of MCU, MICU1 and VDAC2.</title><p>In situ hybridization analysis shows that the expression levels of MCU, MICU1 and VDAC2 are comparable between wild type and <italic>tre</italic> embryos with and without efsevin treatment.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.04801.028">http://dx.doi.org/10.7554/eLife.04801.028</ext-link></p></caption><graphic xlink:href="elife-04801-fig7-figsupp1-v1.tif"/></fig></fig-group></p></sec><sec id="s2-7"><title>Conclusion</title><p>In summary, we conducted a chemical suppressor screen in zebrafish to dissect the regulatory network critical for maintaining rhythmic cardiac contractions and to identify mechanisms underlying aberrant Ca<sup>2+</sup> handling-induced cardiac dysfunction. We show that activation of VDAC2 through overexpression or efsevin treatment potently restores rhythmic contractions in NCX1h deficient zebrafish hearts and effectively suppresses Ca<sup>2+</sup> overload-induced arrhythmogenic Ca<sup>2+</sup> events and irregular contractions in mouse and human cardiomyocytes. We provide evidence that potentiating VDAC2 activity enhances mitochondrial Ca<sup>2+</sup> uptake, accelerates Ca<sup>2+</sup> transfer from intracellular stores into mitochondria and spatially and temporally restricts single Ca<sup>2+</sup> sparks in cardiomyocytes. The crucial role of mitochondria in the regulation of cardiac rhythmicity is further supported by the findings that VDAC2 functions in concert with MCU; these genes have a strong synergistic effect on suppressing cardiac fibrillation and loss of function of either gene abrogates the rescue effect of the other in <italic>tre</italic>.</p><p>The regulatory roles of mitochondrial Ca<sup>2+</sup> in cardiac metabolism, cell survival and fate have been studied extensively (<xref ref-type="bibr" rid="bib8">Brown and O'Rourke, 2010</xref>; <xref ref-type="bibr" rid="bib20">Dorn and Scorrano, 2010</xref>; <xref ref-type="bibr" rid="bib19">Doenst et al., 2013</xref>; <xref ref-type="bibr" rid="bib31">Kasahara et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Kohlhaas and Maack, 2013</xref>; <xref ref-type="bibr" rid="bib36">Luo and Anderson, 2013</xref>). Our study provides genetic and physiologic evidence supporting an additional role for mitochondria in regulating cardiac rhythmicity and reveals VDAC2 as a modulator of Ca<sup>2+</sup> handling in cardiomyocytes. Our findings, together with recent reports of the physical interaction between VDAC2 and RyR2 (<xref ref-type="bibr" rid="bib40">Min et al., 2012</xref>) and the close proximity of outer and inner mitochondrial membranes at the contact sites between the mitochondria and the SR (<xref ref-type="bibr" rid="bib27">García-Pérez et al., 2011</xref>), suggest an intriguing model. We propose that mitochondria facilitate an efficient clearance mechanism in the Ca<sup>2+</sup> microdomain, which modulates Ca<sup>2+</sup> handling without affecting global Ca<sup>2+</sup> signals in cardiomyocytes. In this model, VDAC facilitates mitochondrial Ca<sup>2+</sup> uptake via MCU complex and thereby controls the duration and the diffusion of cytosolic Ca<sup>2+</sup> near the Ca<sup>2+</sup> release sites to ensure rhythmic cardiac contractions. This model is consistent with our observation that efsevin treatment induces faster inactivation kinetics of cytosolic Ca<sup>2+</sup> transients without affecting the amplitude or the time to peak in cardiomyocytes and the reports that blocking mitochondrial Ca<sup>2+</sup> uptake has little impact on cytosolic Ca<sup>2+</sup> transients (<xref ref-type="bibr" rid="bib37">Maack et al., 2006</xref>; <xref ref-type="bibr" rid="bib32">Kohlhaas et al., 2010</xref>). Further support for this model comes from the observation of the Ca<sup>2+</sup> peaks on the OMM (<xref ref-type="bibr" rid="bib21">Drago et al., 2012</xref>) and the finding that downregulating VDAC2 extends Ca<sup>2+</sup> sparks (<xref ref-type="bibr" rid="bib55">Subedi et al., 2011</xref>; <xref ref-type="bibr" rid="bib40">Min et al., 2012</xref>) and that blocking mitochondrial Ca<sup>2+</sup> uptake by Ru360 leads to an increased number of spontaneous propagating Ca<sup>2+</sup> waves (<xref ref-type="bibr" rid="bib51">Seguchi et al., 2005</xref>). Future studies on the kinetics of VDAC2-dependent mitochondrial Ca<sup>2+</sup> uptake and exploring potential regulatory molecules for VDAC2 activity will provide insights into how the crosstalk between SR and mitochondria contributes to Ca<sup>2+</sup> handling and cardiac rhythmicity.</p><p>Aberrant Ca<sup>2+</sup> handling is associated with many cardiac dysfunctions including arrhythmia. Establishing animal models to study molecular mechanisms and develop new therapeutic strategies are therefore major preclinical needs. Our chemical suppressor screen identified a potent effect of efsevin and its biological target VDAC2 on manipulating cardiac Ca<sup>2+</sup> handling and restoring regular cardiac contractions in fish and mouse and human cardiomyocytes. This success indicates that fundamental mechanisms regulating cardiac function are conserved among vertebrates despite the existence of species-specific features and suggests a new paradigm of using zebrafish cardiac disease models for the dissection of critical genetic pathways and the discovery of new therapeutic approaches. Future studies examining the effects of efsevin on other arrhythmia models would further elucidate the potential for efsevin as a pharmacological tool to treat cardiac arrhythmia associated with aberrant Ca<sup>2+</sup> handling.</p></sec></sec><sec id="s3" sec-type="materials|methods"><title>Materials and methods</title><sec id="s3-1"><title>Zebrafish husbandry and transgenic lines</title><p>Zebrafish of the mutant line <italic>tremblor</italic> (<italic>tre</italic><sup><italic>tc318</italic></sup>) were maintained and bred as described previously (<xref ref-type="bibr" rid="bib35">Langenbacher et al., 2005</xref>). Transgenic lines, <italic>myl7:gCaMP4.1</italic><sup><italic>LA2124</italic></sup> and <italic>myl7:VDAC2</italic><sup><italic>LA2309</italic></sup> were created using the Tol2kit (<xref ref-type="bibr" rid="bib23">Esengil et al., 2007</xref>; <xref ref-type="bibr" rid="bib34">Kwan et al., 2007</xref>; <xref ref-type="bibr" rid="bib52">Shindo et al., 2010</xref>). The <italic>VDAC2</italic><sup><italic>LA2256</italic></sup> was created using the zinc finger array OZ523 and OZ524 generated by the zebrafish Zinc Finger Consortium (<xref ref-type="bibr" rid="bib24">Foley et al., 2009a</xref>, <xref ref-type="bibr" rid="bib25">2009b</xref>).</p></sec><sec id="s3-2"><title>Molecular Biology</title><p>Full length VDAC2 cDNA was purchased from Open Biosystems (Huntsville, AL) and cloned into pCS2+ or pCS2+3XFLAG. Full length cDNA fragments of zebrafish MCU (Accession number: JX424822) and MICU1 (JX42823) were amplified from 2 dpf embryos and cloned into pCS2+. For mRNA synthesis, plasmids were linearized and mRNA was synthesized using the SP6 mMESSAGE mMachine kit according to the manufacturers manual (Ambion, Austin, TX.).</p></sec><sec id="s3-3"><title>Zebrafish injections</title><p>VDAC2 mRNA and morpholino antisense oligos (5′-GGGAACGGCCATTTTATCTGTTAAA-3′) (Genetools, Philomath, OR) were injected into one-cell stage embryos collected from crosses of <italic>tre</italic><sup><italic>tc318</italic></sup> heterozygotes. Cardiac performance was analyzed by visual inspection on 1 dpf. The <italic>tre</italic> mutant embryos were identified either by observing the fibrillation phenotype at 2–3 dpf or by genotyping as previously described (<xref ref-type="bibr" rid="bib35">Langenbacher et al., 2005</xref>).</p></sec><sec id="s3-4"><title>Chemical screen</title><p>Chemicals from a synthetic library (<xref ref-type="bibr" rid="bib9">Castellano et al., 2007</xref>; <xref ref-type="bibr" rid="bib13">Choi et al., 2011</xref>; <xref ref-type="bibr" rid="bib14">Cruz et al., 2011</xref>) and from Biomol International LP (Farmingdale, NY) were screened for their ability to partially or completely restore persistent heartbeat in <italic>tre</italic> embryos. 12 embryos collected from crosses of <italic>tre</italic><sup><italic>tc318</italic></sup> heterozygotes were raised in the presence of individual compounds at a concentration of 10 µM from 4 hpf (<xref ref-type="bibr" rid="bib13">Choi et al., 2011</xref>). Cardiac function was analyzed by visual inspection at 1 and 2 dpf. The hearts of <italic>tre</italic><sup><italic>tc318</italic></sup> embryos manifest a chaotic movement resembling cardiac fibrillation with intermittent contractions in rare occasion (<xref ref-type="bibr" rid="bib22">Ebert et al., 2005</xref>; <xref ref-type="bibr" rid="bib35">Langenbacher et al., 2005</xref>). Compounds that elicit persistent coordinated cardiac contractions were validated on large number of <italic>tre</italic> mutant embryos and NCX1h morphants (&gt;500 embryos).</p></sec><sec id="s3-5"><title>Zebrafish cardiac imaging</title><p>Videos of GFP-labelled <italic>myl7:GFP</italic> hearts were taken at 30 frames per second. Line-scan analysis was performed along a line through the atria or the ventricles of these hearts (<xref ref-type="bibr" rid="bib41">Nguyen et al., 2009</xref>). Fraction of shortening was deduced from the ratio of diastolic and systolic width and heart rate was determined by beats per minute. Cardiac parameters were analyzed in <italic>tremblor</italic><sup><italic>tc318</italic></sup> and <italic>VDAC2</italic><sup><italic>LA2256</italic></sup> at 2 dpf.</p></sec><sec id="s3-6"><title>Zebrafish optical mapping</title><p>36 hpf <italic>myl7:gCaMP4.1</italic> embryos were imaged at a frame rate of 30 ms/frame. Electromechanical isolation was achieved by tnnt2MO (<xref ref-type="bibr" rid="bib39">Milan et al., 2006</xref>). The fluorescence intensity of each pixel in a 2D map was normalize to generate heat maps and isochronal lines at 33 ms intervals were obtained by identifying the maximal spatial gradient for a given time point (<xref ref-type="bibr" rid="bib11">Chi et al., 2008</xref>).</p></sec><sec id="s3-7"><title>Mouse and human embryonic stem cells</title><p>The mouse E14Tg2a ESC and human H9 ESC line were cultured and differentiated as previously described (<xref ref-type="bibr" rid="bib5">Blin et al., 2010</xref>; <xref ref-type="bibr" rid="bib1">Arshi et al., 2013</xref>). At day 10 of differentiation, beating mouse EBs were exposed to external solution containing 10 mM CaCl<sub>2</sub> for 10 min before DMSO or efsevin (10 μM) treatment. Human EBs were differentiated for 15 days and treated with 5 mM CaCl<sub>2</sub> for 10 min before DMSO or efsevin (5 μM) treatment. Images of beating EBs were acquired at a rate of 30 frames/s and analyzed by motion-detection software. For calcium recording, the EBs were loaded with 10 μM fluo-4 AM in culture media for 30 min at 37°C. Line-scan analysis was performed and fluorescent signals were acquired by a Zeiss LSM510 confocal microscope.</p></sec><sec id="s3-8"><title>Microelectrode array measurements</title><p>2-day-old wild type, <italic>tre,</italic> and efsevin-treated <italic>tre</italic> embryos were placed on uncoated, microelectrode arrays (MEAs) containing 120 integrated TiN electrodes (30 μm diameter, 200 μm interelectrode spacing). Local field potentials (LFPs) at each electrode were collected for three trials per embryo type over a period of three minutes at a sampling rate of 1 kHz using the MEA2100-HS120 system (Multichannel Systems, Reutiligen, Germany). Raw data was low-pass filtered at a cutoff frequency of 10 Hz using a third-order Butterworth filter. Data analysis was carried out using the MC_DataTool (Multichannel Systems) and Matlab (MathWorks).</p></sec><sec id="s3-9"><title>Ca<sup>2+</sup> imaging</title><p>Murine ventricular cardiomyocytes were isolated as previously described (<xref ref-type="bibr" rid="bib45">Reuter et al., 2004</xref>). Cells were loaded with 5 µM fluo-4 AM in external solution containing: 138.2 mM NaCl, 4.6 mM KCl, 1.2 mM MgCl, 15 mM glucose, 20 mM HEPES for 1 hr and imaged in external solution supplemented with 2, 5 or 10 mM CaCl<sub>2</sub>. For the recording of Ca<sup>2+</sup> sparks and transients, the external solution contained 2 mM CaCl<sub>2</sub>. For Ca<sup>2+</sup> transients, cells were field stimulated at 0.5 Hz with a 5 ms pulse at a voltage of 20% above contraction threshold. For all measurements, efsevin was added 2 hr prior to the actual experiment. Images were recorded on a Zeiss LSM 5 Pascal confocal microscope. Data analysis was carried out using the Zeiss LSM Image Browser and ImageJ with the SparkMaster plugin (<xref ref-type="bibr" rid="bib43">Picht et al., 2007</xref>). Cells were visually inspected prior to and after each recording. Only those recordings from healthy looking cells with distinct borders, uniform striations and no membrane blebs or granularity were included in the analysis.</p></sec><sec id="s3-10"><title>Biochemistry</title><p>For pull down assays mono-N-Boc protected 2,2'-(ethylenedioxy)bis(ethylamine) was attached to the carboxylic ester of efsevin and its derivatives through the amide bond. After removal of the Boc group using TFA, the primary amine was coupled to the carboxylic acid of Affi-Gel 10 Gel (Biorad, Hercules, CA). 2-day-old zebrafish embryos were deyolked by centrifugation before being lysed with Rubinfeld's lysis buffer (<xref ref-type="bibr" rid="bib50">Rubinfeld et al., 1993</xref>). The lysate was precleaned by incubation with Affi-Gel 10 Gel to eliminate non-specific binding. Precleaned lysate was incubated with affinity beads overnight. Proteins were eluted from the affinity beads and separated on SDS-PAGE. Protein bands of interest were excised. Gel plugs were dehydrated in acetonitrile (ACN) and dried completely in a Speedvac. Samples were reduced and alkylated with 10 mM dithiotreitol and 10 mM TCEP solution in 50 mM NH<sub>4</sub>HCO<sub>3</sub> (30 min at 56°C) and 100 mM iodoacetamide (45 min in dark), respectively. Gel plugs were washed with 50 mM NH<sub>4</sub>HCO<sub>3</sub>, dehydrated with ACN, and dried down in a Speedvac. Gel pieces were then swollen in digestion buffer containing 50 mM NH<sub>4</sub>HCO<sub>3</sub>, and 20.0 ng/μl of chymotrypsin (25°C, overnight). Peptides were extracted with 0.1% TFA in 50% ACN solution, dried down and resuspended in LC buffer A (0.1% formic acid, 2% ACN).</p></sec><sec id="s3-11"><title>Mass spectrometry analyses and database searching</title><p>Extracted peptides were analyzed by nano-flow LC/MS/MS on a Thermo Orbitrap with dedicated Eksigent nanopump using a reversed phase column (New Objective, Woburn, MA). The flow rate was 200 nl/min for separation: mobile phase A contained 0.1% formic acid, 2% ACN in water, and mobile phase B contained 0.1% formic acid, 20% water in ACN. The gradient used for analyses was linear from 5% B to 50% B over 60 min, then to 95% B over 15 min, and finally keeping constant 95% B for 10 min. Spectra were acquired in data-dependent mode with dynamic exclusion where the instrument selects the top six most abundant ions in the parent spectra for fragmentation. Data were searched against the <italic>Danio rerio</italic> IPI database v3.45 using the SEQUEST algorithm in the BioWorks software program version 3.3.1 SP1. All spectra used for identification had deltaCN&gt;0.1 and met the following Xcorr criteria: &gt;2 (+1), &gt;3 (+2), &gt;4 (+3), and &gt;5 (+4). Searches required full cleavage with the enzyme, <underline>&lt;</underline>4 missed cleavages and were performed with the differential modifications of carbamidomethylation on cysteine and methionine oxidation.</p></sec><sec id="s3-12"><title>In situ hybridization</title><p>In situ hybridization was performed as previously described (<xref ref-type="bibr" rid="bib10">Chen and Fishman, 1996</xref>). DIG-labeled RNA probe was synthesized using the DIG RNA labeling kit (Roche, Indianapolis, IN).</p></sec><sec id="s3-13"><title>Immunostaining</title><p>HeLa cells were transfected with a C-terminally flag-tagged zebrafish VDAC1 or VDAC2 in plasmid pCS2+ using Lipofectamine 2000 (Invitrogen). After staining with MitoTracker Orange (Invitrogen) cells were fixed in 3.7% formaldehyde and permeabilized with acetone. Immunostaining was performed using primary antibody ANTI-FLAG M2 (Sigma Aldrich, St. Luis, MO) at 1:100 and secondary antibody Anti-Mouse IgG1-FITC (Southern Biotechnology Associates, Birmingham, AL) at 1:200. Cells were mounted and counterstained using Vectashield Hard Set with DAPI (Vector Laboratories, UK).</p></sec><sec id="s3-14"><title>Mitochondria Ca<sup>2+</sup> uptake assay in HeLa cells</title><p>HeLa cells were transfected with zebrafish VDAC2 using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). 36 hrs after transfection, cells were loaded with 5 µM Rhod2-AM (Invitrogen), a Ca<sup>2+</sup> indicator preferentially localized in mitochondria, for 1 hr at 15°C followed by a 30 min de-esterification period at 37°C. Subsequently, cells were permeabilized with 100 µM digitonin for 1 min at room temperature. Fluorescence changes in Rhod2 (ex: 544 nm, em: 590 nm) immediately after the addition of Ca<sup>2+</sup> (final free Ca<sup>2+</sup> concentration is calculated to be approximately 10 µM using WEBMAXC at <ext-link ext-link-type="uri" xlink:href="http://web.stanford.edu/%7Ecpatton/webmaxcS.htm">http://web.stanford.edu/∼cpatton/webmaxcS.htm</ext-link>) were monitored in internal buffer (5 mM K-EGTA, 20 mM HEPES, 100 mM K-aspartate, 40 mM KCl, 1 mM MgCl<sub>2</sub>, 2 mM maleic acid, 2 mM glutamic acid, 5 mM pyruvic acid, 0.5 mM KH<sub>2</sub>PO<sub>4</sub>, 5 mM MgATP, pH adjusted to 7.2 with Trizma base) using a FLUOSTAR plate reader (BMG Labtech, Germany).</p></sec><sec id="s3-15"><title>Mitochondria Ca<sup>2+</sup> uptake assay in VDAC1/VDAC3 double knockout (V1/V3 DKO) MEFs</title><p>V1/V3 DKO MEFs were cultured as previously described (<xref ref-type="bibr" rid="bib48">Roy et al., 2009a</xref>). Efsevin-treated (15 μM for 30 min) or mock-treated MEFs were used for measurements of [Ca<sup>2+</sup>]<sub>c</sub> in suspensions of permeabilized cells or imaging of [Ca<sup>2+</sup>]<sub>m</sub> simultaneously with [Ca<sup>2+</sup>]<sub>c</sub> in intact single cells. Permeabilization of the plasma membrane was performed by digitonin (40 μM/ml). Changes in [Ca<sup>2+</sup>] in the cytoplasmic buffer upon IP<sub>3</sub> (7.5 μM) addition in the presence or absence of ruthenium red (3 μM) was measured by fura2 in a fluorometer (<xref ref-type="bibr" rid="bib16">Csordás et al., 2006</xref>; <xref ref-type="bibr" rid="bib49">Roy et al., 2009b</xref>). To avoid endoplasmic reticulum Ca<sup>2+</sup> uptake 2 μM thapsigargin was added before IP<sub>3</sub>. For imaging of [Ca<sup>2+</sup>]<sub>m</sub> and [Ca<sup>2+</sup>]<sub>c</sub>, MEFs were co-transfected with plasmids encoding polycistronic zebrafish VDAC2 with mCherry and mitochondria-targeted inverse pericam for 40 hr. Cells were sorted to enrich the transfected cells and attached to glass coverslips. In the final 10 min, of the efsevin or mock-treatment, the cells were also loaded with fura2AM (2.5 μM) and subsequently transferred to the microscope stage. Stimulation with 1 μM ATP was carried out in a norminally Ca<sup>2+</sup> free buffer. Changes in [Ca<sup>2+</sup>]<sub>c</sub> and [Ca<sup>2+</sup>]<sub>m</sub> were imaged using fura2 (ratio of ex:340 nm–380 nm) and mitochondria-targeted inverse pericam (ex: 495 nm), respectively (<xref ref-type="bibr" rid="bib17">Csordas et al., 2010</xref>).</p></sec><sec id="s3-16"><title>Statistics</title><p>All values are expressed as mean ± SEM, unless otherwise specified. Significance values are calculated by unpaired student's t-test unless noted otherwise.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors thank Kenneth D Philipson, James N Weiss and Adam D Langenbacher for comments on the manuscript, Janice Ahn for assisting the initial chemical screen and Lingling Peng for the synthesis and Yi Chiao Fan for the characterization of efsevin and its derivatives. We also thank Jing Huang, James N Weiss and the UCLA cardiovascular research laboratory for reagents and infrastructure, and Jinghua Tang of UCLA-BSCRC for technical assistance on human ES cell works. We thank William Craigen for providing V1/V3 DKO MEFs.</p></ack><sec sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>HS, Designed, performed, analyzed, and interpreted experiments, Wrote the manuscript, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>JS, Designed, performed, analyzed, and interpreted experiments, Wrote the manuscript, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>JH, Designed, performed, analyzed, and interpreted experiments, Conception and design, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con4"><p>KL, Designed and synthesized the compound library and all efsevin used for experiments, Conception and design, Acquisition of data</p></fn><fn fn-type="con" id="con5"><p>SN, Examined mitochondrial Ca<sup>2+</sup> uptake in V1/V3KO MEFs, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con6"><p>AE, Examined mitochondrial Ca<sup>2+</sup> uptake in V1/V3KO MEFs, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con7"><p>FL, Performed, analyzed, and interpreted experiments, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con8"><p>KW, Performed, analyzed, and interpreted experiments, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con9"><p>CT, Performed, analyzed, and interpreted experiments, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con10"><p>SF, Designed and performed the mass-spec analysis, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con11"><p>HDGF, Designed and synthesized the compound library and all efsevin used for experiments, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con12"><p>HZ, Designed and performed MEA analysis, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con13"><p>BL, Performed, analyzed, and interpreted experiments, Acquisition of data</p></fn><fn fn-type="con" id="con14"><p>HN, Designed and performed hESC-CM experiments, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con15"><p>JN, Provided gCaMP construct, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con16"><p>AZS, Designed and interpreted MEA analysis, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con17"><p>JKG, Designed and interpreted MEA analysis, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con18"><p>AN, Designed and performed hESC-CM experiments, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con19"><p>JIG, Supervised physiological analysis, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con20"><p>TMV, Designed and performed the mass-spec analysis, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con21"><p>GH, Examined mitochondrial Ca<sup>2+</sup> uptake in V1/V3KO MEFsDesigned and formulated hypothesis, Designed and synthesized the compound library and all efsevin used for experiments, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con22"><p>OK, Designed and synthesized the compound library and all efsevin used for experiments, Conception and design, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con23"><p>J-NC, Designed and formulated hypothesis, Performed, analyzed, and interpreted experiments, Wrote the manuscript, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the University of California, Los Angeles and the Cedars-Sinai Hospital. The protocols were approved by the Cedars-Sinai Institutional Animal Care and Use Committee (#003574 for the use of mouse cardiomyocytes), the Office of Animal Research Oversight that oversees the Ethics of Animal Experiments (ARC# 2000-051-43B for the use of zebrafish) and Embryonic Stem Cell Research Oversight (#2009-006-06 for the use of ES cells) of the University of California, Los Angeles. Every effort was made to minimize suffering.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arshi</surname><given-names>A</given-names></name><name><surname>Nakashima</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Eaimkhong</surname><given-names>S</given-names></name><name><surname>Evseenko</surname><given-names>D</given-names></name><name><surname>Reed</surname><given-names>J</given-names></name><name><surname>Stieg</surname><given-names>AZ</given-names></name><name><surname>Gimzewski</surname><given-names>JK</given-names></name><name><surname>Nakano</surname><given-names>A</given-names></name></person-group><year>2013</year><article-title>Rigid microenvironments promote cardiac differentiation of mouse and human embryonic stem cells</article-title><source>Science and Technology of Advanced Materials</source><volume>14</volume><comment>pii: 025003</comment><pub-id pub-id-type="doi">10.1088/1468-6996/14/2/025003</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bathori</surname><given-names>G</given-names></name><name><surname>Csordas</surname><given-names>G</given-names></name><name><surname>Garcia-Perez</surname><given-names>C</given-names></name><name><surname>Davies</surname><given-names>E</given-names></name><name><surname>Hajnoczky</surname><given-names>G</given-names></name></person-group><year>2006</year><article-title>Ca2+-dependent control of the permeability properties of the mitochondrial outer membrane and voltage-dependent anion-selective channel (VDAC)</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>17347</fpage><lpage>17358</lpage><pub-id pub-id-type="doi">10.1074/jbc.M600906200</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baughman</surname><given-names>JM</given-names></name><name><surname>Perocchi</surname><given-names>F</given-names></name><name><surname>Girgis</surname><given-names>HS</given-names></name><name><surname>Plovanich</surname><given-names>M</given-names></name><name><surname>Belcher-Timme</surname><given-names>CA</given-names></name><name><surname>Sancak</surname><given-names>Y</given-names></name><name><surname>Bao</surname><given-names>XR</given-names></name><name><surname>Strittmatter</surname><given-names>L</given-names></name><name><surname>Goldberger</surname><given-names>O</given-names></name><name><surname>Bogorad</surname><given-names>RL</given-names></name><name><surname>Koteliansky</surname><given-names>V</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name></person-group><year>2011</year><article-title>Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter</article-title><source>Nature</source><volume>476</volume><fpage>341</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nature10234</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bers</surname><given-names>DM</given-names></name></person-group><year>2002</year><article-title>Cardiac excitation-contraction coupling</article-title><source>Nature</source><volume>415</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1038/415198a</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blin</surname><given-names>G</given-names></name><name><surname>Nury</surname><given-names>D</given-names></name><name><surname>Stefanovic</surname><given-names>S</given-names></name><name><surname>Neri</surname><given-names>T</given-names></name><name><surname>Guillevic</surname><given-names>O</given-names></name><name><surname>Brinon</surname><given-names>B</given-names></name><name><surname>Bellamy</surname><given-names>V</given-names></name><name><surname>Rucker-Martin</surname><given-names>C</given-names></name><name><surname>Barbry</surname><given-names>P</given-names></name><name><surname>Bel</surname><given-names>A</given-names></name><name><surname>Bruneval</surname><given-names>P</given-names></name><name><surname>Cowan</surname><given-names>C</given-names></name><name><surname>Pouly</surname><given-names>J</given-names></name><name><surname>Mitalipov</surname><given-names>S</given-names></name><name><surname>Gouadon</surname><given-names>E</given-names></name><name><surname>Binder</surname><given-names>P</given-names></name><name><surname>Hagège</surname><given-names>A</given-names></name><name><surname>Desnos</surname><given-names>M</given-names></name><name><surname>Renaud</surname><given-names>JF</given-names></name><name><surname>Menasché</surname><given-names>P</given-names></name><name><surname>Pucéat</surname><given-names>M</given-names></name></person-group><year>2010</year><article-title>A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates</article-title><source>The Journal of Clinical Investigation</source><volume>120</volume><fpage>1125</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1172/JCI40120</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boncompagni</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>AE</given-names></name><name><surname>Micaroni</surname><given-names>M</given-names></name><name><surname>Beznoussenko</surname><given-names>GV</given-names></name><name><surname>Polishchuk</surname><given-names>RS</given-names></name><name><surname>Dirksen</surname><given-names>RT</given-names></name><name><surname>Protasi</surname><given-names>F</given-names></name></person-group><year>2009</year><article-title>Mitochondria are linked to calcium stores in striated muscle by developmentally regulated tethering structures</article-title><source>Molecular Biology of the Cell</source><volume>20</volume><fpage>1058</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.1091/mbc.E08-07-0783</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandes</surname><given-names>R</given-names></name><name><surname>Bers</surname><given-names>DM</given-names></name></person-group><year>1997</year><article-title>Intracellular Ca2+ increases the mitochondrial NADH concentration during elevated work in intact cardiac muscle</article-title><source>Circulation Research</source><volume>80</volume><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1161/01.RES.80.1.82</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>DA</given-names></name><name><surname>O'Rourke</surname><given-names>B</given-names></name></person-group><year>2010</year><article-title>Cardiac mitochondria and arrhythmias</article-title><source>Cardiovascular Research</source><volume>88</volume><fpage>241</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvq231</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellano</surname><given-names>S</given-names></name><name><surname>Fiji</surname><given-names>HD</given-names></name><name><surname>Kinderman</surname><given-names>SS</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Leon</surname><given-names>P</given-names></name><name><surname>Tamanoi</surname><given-names>F</given-names></name><name><surname>Kwon</surname><given-names>O</given-names></name></person-group><year>2007</year><article-title>Small-molecule inhibitors of protein geranylgeranyltransferase type I</article-title><source>Journal of the American Chemical Society</source><volume>129</volume><fpage>5843</fpage><lpage>5845</lpage><pub-id pub-id-type="doi">10.1021/ja070274n</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JN</given-names></name><name><surname>Fishman</surname><given-names>MC</given-names></name></person-group><year>1996</year><article-title>Zebrafish tinman homolog demarcates the heart field and initiates myocardial differentiation</article-title><source>Development</source><volume>122</volume><fpage>3809</fpage><lpage>3816</lpage></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>NC</given-names></name><name><surname>Shaw</surname><given-names>RM</given-names></name><name><surname>Jungblut</surname><given-names>B</given-names></name><name><surname>Huisken</surname><given-names>J</given-names></name><name><surname>Ferrer</surname><given-names>T</given-names></name><name><surname>Arnaout</surname><given-names>R</given-names></name><name><surname>Scott</surname><given-names>I</given-names></name><name><surname>Beis</surname><given-names>D</given-names></name><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Baier</surname><given-names>H</given-names></name><name><surname>Jan</surname><given-names>LY</given-names></name><name><surname>Tristani-Firouzi</surname><given-names>M</given-names></name><name><surname>Stainier</surname><given-names>DY</given-names></name></person-group><year>2008</year><article-title>Genetic and physiologic dissection of the vertebrate cardiac conduction system</article-title><source>PLOS Biology</source><volume>6</volume><fpage>e109</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.0060109</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>BR</given-names></name><name><surname>Burton</surname><given-names>F</given-names></name><name><surname>Salama</surname><given-names>G</given-names></name></person-group><year>2002</year><article-title>Cytosolic Ca2+ triggers early afterdepolarization and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome</article-title><source>The Journal of Physiology</source><volume>543</volume><fpage>615</fpage><lpage>631</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2002.024570</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Mouillesseaux</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Fiji</surname><given-names>HD</given-names></name><name><surname>Kinderman</surname><given-names>SS</given-names></name><name><surname>Otto</surname><given-names>GW</given-names></name><name><surname>Geisler</surname><given-names>R</given-names></name><name><surname>Kwon</surname><given-names>O</given-names></name><name><surname>Chen</surname><given-names>JN</given-names></name></person-group><year>2011</year><article-title>Aplexone targets the HMG-CoA reductase pathway and differentially regulates arterovenous angiogenesis</article-title><source>Development</source><volume>138</volume><fpage>1173</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1242/dev.054049</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Kibbie</surname><given-names>J</given-names></name><name><surname>Modlin</surname><given-names>R</given-names></name><name><surname>Kwon</surname><given-names>O</given-names></name></person-group><year>2011</year><article-title>Diversity through phosphine catalysis identifies octahydro-1,6-naphthyridin-4-ones as activators of endothelium-driven immunity</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>108</volume><fpage>6769</fpage><lpage>6774</lpage><pub-id pub-id-type="doi">10.1073/pnas.1015254108</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csordas</surname><given-names>G</given-names></name><name><surname>Golenar</surname><given-names>T</given-names></name><name><surname>Seifert</surname><given-names>EL</given-names></name><name><surname>Kamer</surname><given-names>KJ</given-names></name><name><surname>Sancak</surname><given-names>Y</given-names></name><name><surname>Perocchi</surname><given-names>F</given-names></name><name><surname>Moffat</surname><given-names>C</given-names></name><name><surname>Weaver</surname><given-names>D</given-names></name><name><surname>de la Fuente Perez</surname><given-names>S</given-names></name><name><surname>Bogorad</surname><given-names>R</given-names></name><name><surname>Koteliansky</surname><given-names>V</given-names></name><name><surname>Adijanto</surname><given-names>J</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Hajnóczky</surname><given-names>G</given-names></name></person-group><year>2013</year><article-title>MICU1 controls both the Threshold and Cooperative activation of the mitochondrial Ca<sup>2+</sup> uniporter</article-title><source>Cell Metabolism</source><volume>17</volume><fpage>976</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.04.020</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csordás</surname><given-names>G</given-names></name><name><surname>Renken</surname><given-names>C</given-names></name><name><surname>Varnai</surname><given-names>P</given-names></name><name><surname>Walter</surname><given-names>L</given-names></name><name><surname>Weaver</surname><given-names>D</given-names></name><name><surname>Buttle</surname><given-names>KF</given-names></name><name><surname>Balla</surname><given-names>T</given-names></name><name><surname>Mannella</surname><given-names>CA</given-names></name><name><surname>Hajnoczky</surname><given-names>G</given-names></name></person-group><year>2006</year><article-title>Structural and functional features and significance of the physical linkage between ER and mitochondria</article-title><source>The Journal of Cell Biology</source><volume>174</volume><fpage>915</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1083/jcb.200604016</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csordas</surname><given-names>G</given-names></name><name><surname>Varnai</surname><given-names>P</given-names></name><name><surname>Golenar</surname><given-names>T</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Purkins</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>TG</given-names></name><name><surname>Balla</surname><given-names>T</given-names></name><name><surname>Hajnoczky</surname><given-names>G</given-names></name></person-group><year>2010</year><article-title>Imaging interorganelle contacts and local calcium dynamics at the ER-mitochondrial interface</article-title><source>Molecular Cell</source><volume>39</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.06.029</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Stefani</surname><given-names>D</given-names></name><name><surname>Raffaello</surname><given-names>A</given-names></name><name><surname>Teardo</surname><given-names>E</given-names></name><name><surname>Szabo</surname><given-names>I</given-names></name><name><surname>Rizzuto</surname><given-names>R</given-names></name></person-group><year>2011</year><article-title>A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter</article-title><source>Nature</source><volume>476</volume><fpage>336</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1038/nature10230</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doenst</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Abel</surname><given-names>ED</given-names></name></person-group><year>2013</year><article-title>Cardiac metabolism in heart failure: implications beyond ATP production</article-title><source>Circulation Research</source><volume>113</volume><fpage>709</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.300376</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorn</surname><given-names>GW</given-names><suffix>II</suffix></name><name><surname>Scorrano</surname><given-names>L</given-names></name></person-group><year>2010</year><article-title>Two close, too close: sarcoplasmic reticulum-mitochondrial crosstalk and cardiomyocyte fate</article-title><source>Circulation Research</source><volume>107</volume><fpage>689</fpage><lpage>699</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.225714</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drago</surname><given-names>I</given-names></name><name><surname>De Stefani</surname><given-names>D</given-names></name><name><surname>Rizzuto</surname><given-names>R</given-names></name><name><surname>Pozzan</surname><given-names>T</given-names></name></person-group><year>2012</year><article-title>Mitochondrial Ca2+ uptake contributes to buffering cytoplasmic Ca2+ peaks in cardiomyocytes</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>109</volume><fpage>12986</fpage><lpage>12991</lpage><pub-id pub-id-type="doi">10.1073/pnas.1210718109</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>AM</given-names></name><name><surname>Hume</surname><given-names>GL</given-names></name><name><surname>Warren</surname><given-names>KS</given-names></name><name><surname>Cook</surname><given-names>NP</given-names></name><name><surname>Burns</surname><given-names>CG</given-names></name><name><surname>Mohideen</surname><given-names>MA</given-names></name><name><surname>Siegal</surname><given-names>G</given-names></name><name><surname>Yelon</surname><given-names>D</given-names></name><name><surname>Fishman</surname><given-names>MC</given-names></name><name><surname>Garrity</surname><given-names>DM</given-names></name></person-group><year>2005</year><article-title>Calcium extrusion is critical for cardiac morphogenesis and rhythm in embryonic zebrafish hearts</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>102</volume><fpage>17705</fpage><lpage>17710</lpage><pub-id pub-id-type="doi">10.1073/pnas.0502683102</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esengil</surname><given-names>H</given-names></name><name><surname>Chang</surname><given-names>V</given-names></name><name><surname>Mich</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>JK</given-names></name></person-group><year>2007</year><article-title>Small-molecule regulation of zebrafish gene expression</article-title><source>Nature Chemical Biology</source><volume>3</volume><fpage>154</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1038/nchembio858</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Maeder</surname><given-names>ML</given-names></name><name><surname>Pearlberg</surname><given-names>J</given-names></name><name><surname>Joung</surname><given-names>JK</given-names></name><name><surname>Peterson</surname><given-names>RT</given-names></name><name><surname>Yeh</surname><given-names>JR</given-names></name></person-group><year>2009a</year><article-title>Targeted mutagenesis in zebrafish using customized zinc-finger nucleases</article-title><source>Nature Protocols</source><volume>4</volume><fpage>1855</fpage><lpage>1867</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.209</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Yeh</surname><given-names>JR</given-names></name><name><surname>Maeder</surname><given-names>ML</given-names></name><name><surname>Reyon</surname><given-names>D</given-names></name><name><surname>Sander</surname><given-names>JD</given-names></name><name><surname>Peterson</surname><given-names>RT</given-names></name><name><surname>Joung</surname><given-names>JK</given-names></name></person-group><year>2009b</year><article-title>Rapid mutation of endogenous zebrafish genes using zinc finger nucleases made by Oligomerized Pool ENgineering (OPEN)</article-title><source>PLOS ONE</source><volume>4</volume><fpage>e4348</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0004348</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Pérez</surname><given-names>C</given-names></name><name><surname>Hajnóczky</surname><given-names>G</given-names></name><name><surname>Csordás</surname><given-names>G</given-names></name></person-group><year>2008</year><article-title>Physical coupling supports the local Ca2+ transfer between sarcoplasmic reticulum subdomains and the mitochondria in heart muscle</article-title><source>The Journal of Biological Chemistry</source><volume>283</volume><fpage>32771</fpage><lpage>32780</lpage><pub-id pub-id-type="doi">10.1074/jbc.M803385200</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Pérez</surname><given-names>C</given-names></name><name><surname>Schneider</surname><given-names>TG</given-names></name><name><surname>Hajnoczky</surname><given-names>G</given-names></name><name><surname>Csordas</surname><given-names>G</given-names></name></person-group><year>2011</year><article-title>Alignment of sarcoplasmic reticulum-mitochondrial junctions with mitochondrial contact points</article-title><source>American Journal of Physiology Heart and Circulatory Physiology</source><volume>301</volume><fpage>H1907</fpage><lpage>H1915</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00397.2011</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greiser</surname><given-names>M</given-names></name><name><surname>Lederer</surname><given-names>WJ</given-names></name><name><surname>Schotten</surname><given-names>U</given-names></name></person-group><year>2011</year><article-title>Alterations of atrial Ca(2+) handling as cause and consequence of atrial fibrillation</article-title><source>Cardiovascular Research</source><volume>89</volume><fpage>722</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvq389</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajnóczky</surname><given-names>G</given-names></name><name><surname>Robb-Gaspers</surname><given-names>LD</given-names></name><name><surname>Seitz</surname><given-names>MB</given-names></name><name><surname>Thomas</surname><given-names>AP</given-names></name></person-group><year>1995</year><article-title>Decoding of cytosolic calcium oscillations in the mitochondria</article-title><source>Cell</source><volume>82</volume><fpage>415</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90430-1</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Martone</surname><given-names>ME</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Thor</surname><given-names>A</given-names></name><name><surname>Doi</surname><given-names>M</given-names></name><name><surname>Holst</surname><given-names>MJ</given-names></name><name><surname>Ellisman</surname><given-names>MH</given-names></name><name><surname>Hoshijima</surname><given-names>M</given-names></name></person-group><year>2009</year><article-title>Three-dimensional electron microscopy reveals new details of membrane systems for Ca2+ signaling in the heart</article-title><source>Journal of Cell Science</source><volume>122</volume><fpage>1005</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1242/jcs.028175</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>A</given-names></name><name><surname>Cipolat</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names><suffix>II</suffix></name><name><surname>Scorrano</surname><given-names>L</given-names></name></person-group><year>2013</year><article-title>Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling</article-title><source>Science</source><volume>342</volume><fpage>734</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1126/science.1241359</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohlhaas</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Knopp</surname><given-names>A</given-names></name><name><surname>Zeller</surname><given-names>T</given-names></name><name><surname>Ong</surname><given-names>MF</given-names></name><name><surname>Bohm</surname><given-names>M</given-names></name><name><surname>O'Rourke</surname><given-names>B</given-names></name><name><surname>Maack</surname><given-names>C</given-names></name></person-group><year>2010</year><article-title>Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes</article-title><source>Circulation</source><volume>121</volume><fpage>1606</fpage><lpage>1613</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.914911</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohlhaas</surname><given-names>M</given-names></name><name><surname>Maack</surname><given-names>C</given-names></name></person-group><year>2013</year><article-title>Calcium release microdomains and mitochondria</article-title><source>Cardiovascular Research</source><volume>98</volume><fpage>259</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt032</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwan</surname><given-names>KM</given-names></name><name><surname>Fujimoto</surname><given-names>E</given-names></name><name><surname>Grabher</surname><given-names>C</given-names></name><name><surname>Mangum</surname><given-names>BD</given-names></name><name><surname>Hardy</surname><given-names>ME</given-names></name><name><surname>Campbell</surname><given-names>DS</given-names></name><name><surname>Parant</surname><given-names>JM</given-names></name><name><surname>Yost</surname><given-names>HJ</given-names></name><name><surname>Kanki</surname><given-names>JP</given-names></name><name><surname>Chien</surname><given-names>CB</given-names></name></person-group><year>2007</year><article-title>The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs</article-title><source>Developmental Dynamics</source><volume>236</volume><fpage>3088</fpage><lpage>3099</lpage><pub-id pub-id-type="doi">10.1002/dvdy.21343</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langenbacher</surname><given-names>AD</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Shu</surname><given-names>X</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Nicoll</surname><given-names>DA</given-names></name><name><surname>Goldhaber</surname><given-names>JI</given-names></name><name><surname>Philipson</surname><given-names>KD</given-names></name><name><surname>Chen</surname><given-names>JN</given-names></name></person-group><year>2005</year><article-title>Mutation in sodium-calcium exchanger 1 (NCX1) causes cardiac fibrillation in zebrafish</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>102</volume><fpage>17699</fpage><lpage>17704</lpage><pub-id pub-id-type="doi">10.1073/pnas.0502679102</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>ME</given-names></name></person-group><year>2013</year><article-title>Mechanisms of altered Ca<sup>2+</sup> handling in heart failure</article-title><source>Circulation Research</source><volume>113</volume><fpage>690</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.301651</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maack</surname><given-names>C</given-names></name><name><surname>Cortassa</surname><given-names>S</given-names></name><name><surname>Aon</surname><given-names>MA</given-names></name><name><surname>Ganesan</surname><given-names>AN</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>O'Rourke</surname><given-names>B</given-names></name></person-group><year>2006</year><article-title>Elevated cytosolic Na+ decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes</article-title><source>Circulation Research</source><volume>99</volume><fpage>172</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000232546.92777.05</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallilankaraman</surname><given-names>K</given-names></name><name><surname>Doonan</surname><given-names>P</given-names></name><name><surname>Cardenas</surname><given-names>C</given-names></name><name><surname>Chandramoorthy</surname><given-names>HC</given-names></name><name><surname>Muller</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>R</given-names></name><name><surname>Hoffman</surname><given-names>NE</given-names></name><name><surname>Gandhirajan</surname><given-names>RK</given-names></name><name><surname>Molgo</surname><given-names>J</given-names></name><name><surname>Birnbaum</surname><given-names>MJ</given-names></name><name><surname>Rothberg</surname><given-names>BS</given-names></name><name><surname>Mak</surname><given-names>DO</given-names></name><name><surname>Foskett</surname><given-names>JK</given-names></name><name><surname>Madesh</surname><given-names>M</given-names></name></person-group><year>2012</year><article-title>MICU1 is an essential gatekeeper for MCU-mediated mitochondrial Ca(2+) uptake that regulates cell survival</article-title><source>Cell</source><volume>151</volume><fpage>630</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.10.011</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milan</surname><given-names>DJ</given-names></name><name><surname>Giokas</surname><given-names>AC</given-names></name><name><surname>Serluca</surname><given-names>FC</given-names></name><name><surname>Peterson</surname><given-names>RT</given-names></name><name><surname>MacRae</surname><given-names>CA</given-names></name></person-group><year>2006</year><article-title>Notch1b and neuregulin are required for specification of central cardiac conduction tissue</article-title><source>Development</source><volume>133</volume><fpage>1125</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1242/dev.02279</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>CK</given-names></name><name><surname>Yeom</surname><given-names>DR</given-names></name><name><surname>Lee</surname><given-names>KE</given-names></name><name><surname>Kwon</surname><given-names>HK</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Park</surname><given-names>ZY</given-names></name><name><surname>Jeon</surname><given-names>H</given-names></name><name><surname>Kim do</surname><given-names>H</given-names></name></person-group><year>2012</year><article-title>Coupling of ryanodine receptor 2 and voltage-dependent anion channel 2 is essential for Ca<sup>2+</sup> transfer from the sarcoplasmic reticulum to the mitochondria in the heart</article-title><source>The Biochemical Journal</source><volume>447</volume><fpage>371</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1042/BJ20120705</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>CT</given-names></name><name><surname>Qing</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J-N</given-names></name></person-group><year>2009</year><article-title>Zebrafish as a model for cardiovascular development and disease</article-title><source>Drug Discovery Today Disease Models</source><volume>5</volume><fpage>135</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.ddmod.2009.02.003</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perocchi</surname><given-names>F</given-names></name><name><surname>Gohil</surname><given-names>VM</given-names></name><name><surname>Girgis</surname><given-names>HS</given-names></name><name><surname>Bao</surname><given-names>XR</given-names></name><name><surname>McCombs</surname><given-names>JE</given-names></name><name><surname>Palmer</surname><given-names>AE</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name></person-group><year>2010</year><article-title>MICU1 encodes a mitochondrial EF hand protein required for Ca(2+) uptake</article-title><source>Nature</source><volume>467</volume><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1038/nature09358</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picht</surname><given-names>E</given-names></name><name><surname>Zima</surname><given-names>AV</given-names></name><name><surname>Blatter</surname><given-names>LA</given-names></name><name><surname>Bers</surname><given-names>DM</given-names></name></person-group><year>2007</year><article-title>SparkMaster: automated calcium spark analysis with ImageJ</article-title><source>American Journal of Physiology Cell Physiology</source><volume>293</volume><fpage>C1073</fpage><lpage>C1081</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00586.2006</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapizzi</surname><given-names>E</given-names></name><name><surname>Pinton</surname><given-names>P</given-names></name><name><surname>Szabadkai</surname><given-names>G</given-names></name><name><surname>Wieckowski</surname><given-names>MR</given-names></name><name><surname>Vandecasteele</surname><given-names>G</given-names></name><name><surname>Baird</surname><given-names>G</given-names></name><name><surname>Tuft</surname><given-names>RA</given-names></name><name><surname>Fogarty</surname><given-names>KE</given-names></name><name><surname>Rizzuto</surname><given-names>R</given-names></name></person-group><year>2002</year><article-title>Recombinant expression of the voltage-dependent anion channel enhances the transfer of Ca2+ microdomains to mitochondria</article-title><source>The Journal of Cell Biology</source><volume>159</volume><fpage>613</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1083/jcb.200205091</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reuter</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Motter</surname><given-names>C</given-names></name><name><surname>Philipson</surname><given-names>KD</given-names></name><name><surname>Goldhaber</surname><given-names>JI</given-names></name></person-group><year>2004</year><article-title>Mice overexpressing the cardiac sodium-calcium exchanger: defects in excitation-contraction coupling</article-title><source>The Journal of Physiology</source><volume>554</volume><fpage>779</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2003.055046</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzuto</surname><given-names>R</given-names></name><name><surname>Bastianutto</surname><given-names>C</given-names></name><name><surname>Brini</surname><given-names>M</given-names></name><name><surname>Murgia</surname><given-names>M</given-names></name><name><surname>Pozzan</surname><given-names>T</given-names></name></person-group><year>1994</year><article-title>Mitochondrial Ca2+ homeostasis in intact cells</article-title><source>The Journal of Cell Biology</source><volume>126</volume><fpage>1183</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.1083/jcb.126.5.1183</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rottbauer</surname><given-names>W</given-names></name><name><surname>Baker</surname><given-names>K</given-names></name><name><surname>Wo</surname><given-names>ZG</given-names></name><name><surname>Mohideen</surname><given-names>MA</given-names></name><name><surname>Cantiello</surname><given-names>HF</given-names></name><name><surname>Fishman</surname><given-names>MC</given-names></name></person-group><year>2001</year><article-title>Growth and function of the embryonic heart depend upon the cardiac-specific L-type calcium channel alpha1 subunit</article-title><source>Developmental Cell</source><volume>1</volume><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/S1534-5807(01)00023-5</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>SS</given-names></name><name><surname>Ehrlich</surname><given-names>AM</given-names></name><name><surname>Craigen</surname><given-names>WJ</given-names></name><name><surname>Hajnoczky</surname><given-names>G</given-names></name></person-group><year>2009a</year><article-title>VDAC2 is required for truncated BID-induced mitochondrial apoptosis by recruiting BAK to the mitochondria</article-title><source>EMBO Reports</source><volume>10</volume><fpage>1341</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.1038/embor.2009.219</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>SS</given-names></name><name><surname>Madesh</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>E</given-names></name><name><surname>Antonsson</surname><given-names>B</given-names></name><name><surname>Danial</surname><given-names>N</given-names></name><name><surname>Hajnoczky</surname><given-names>G</given-names></name></person-group><year>2009b</year><article-title>Bad targets the permeability transition pore independent of Bax or Bak to switch between Ca2+-dependent cell survival and death</article-title><source>Molecular Cell</source><volume>33</volume><fpage>377</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2009.01.018</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubinfeld</surname><given-names>B</given-names></name><name><surname>Souza</surname><given-names>B</given-names></name><name><surname>Albert</surname><given-names>I</given-names></name><name><surname>Muller</surname><given-names>O</given-names></name><name><surname>Chamberlain</surname><given-names>SH</given-names></name><name><surname>Masiarz</surname><given-names>FR</given-names></name><name><surname>Munemitsu</surname><given-names>S</given-names></name><name><surname>Polakis</surname><given-names>P</given-names></name></person-group><year>1993</year><article-title>Association of the APC gene product with beta-catenin</article-title><source>Science</source><volume>262</volume><fpage>1731</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1126/science.8259518</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seguchi</surname><given-names>H</given-names></name><name><surname>Ritter</surname><given-names>M</given-names></name><name><surname>Shizukuishi</surname><given-names>M</given-names></name><name><surname>Ishida</surname><given-names>H</given-names></name><name><surname>Chokoh</surname><given-names>G</given-names></name><name><surname>Nakazawa</surname><given-names>H</given-names></name><name><surname>Spitzer</surname><given-names>KW</given-names></name><name><surname>Barry</surname><given-names>WH</given-names></name></person-group><year>2005</year><article-title>Propagation of Ca2+ release in cardiac myocytes: role of mitochondria</article-title><source>Cell Calcium</source><volume>38</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2005.03.004</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shindo</surname><given-names>A</given-names></name><name><surname>Hara</surname><given-names>Y</given-names></name><name><surname>Yamamoto</surname><given-names>TS</given-names></name><name><surname>Ohkura</surname><given-names>M</given-names></name><name><surname>Nakai</surname><given-names>J</given-names></name><name><surname>Ueno</surname><given-names>N</given-names></name></person-group><year>2010</year><article-title>Tissue-tissue interaction-triggered calcium elevation is required for cell polarization during Xenopus gastrulation</article-title><source>PLOS ONE</source><volume>5</volume><fpage>e8897</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0008897</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoshan-Barmatz</surname><given-names>V</given-names></name><name><surname>De Pinto</surname><given-names>V</given-names></name><name><surname>Zweckstetter</surname><given-names>M</given-names></name><name><surname>Raviv</surname><given-names>Z</given-names></name><name><surname>Keinan</surname><given-names>N</given-names></name><name><surname>Arbel</surname><given-names>N</given-names></name></person-group><year>2010</year><article-title>VDAC, a multi-functional mitochondrial protein regulating cell life and death</article-title><source>Molecular Aspects of Medicine</source><volume>31</volume><fpage>227</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.mam.2010.03.002</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Joseph</surname><given-names>E</given-names></name><name><surname>Tsai</surname><given-names>HJ</given-names></name><name><surname>Chen</surname><given-names>JN</given-names></name></person-group><year>2003</year><article-title>Na,K-ATPase is essential for embryonic heart development in the zebrafish</article-title><source>Development</source><volume>130</volume><fpage>6165</fpage><lpage>6173</lpage><pub-id pub-id-type="doi">10.1242/dev.00844</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subedi</surname><given-names>KP</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Son</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Woo</surname><given-names>SH</given-names></name></person-group><year>2011</year><article-title>Voltage-dependent anion channel 2 modulates resting Ca<sup>2+</sup> sparks, but not action potential-induced Ca<sup>2+</sup> signaling in cardiac myocytes</article-title><source>Cell Calcium</source><volume>49</volume><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2010.12.004</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Colombini</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>VDAC closure increases calcium ion flux</article-title><source>Biochimica Et Biophysica Acta</source><volume>1768</volume><fpage>2510</fpage><lpage>2515</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2007.06.002</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yano</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Matsuzaki</surname><given-names>M</given-names></name></person-group><year>2008</year><article-title>Defective Ca2+ cycling as a key pathogenic mechanism of heart failure</article-title><source>Circulation Journal</source><volume>72</volume><fpage>A22</fpage><lpage>A30</lpage><pub-id pub-id-type="doi">10.1253/circj.CJ-08-0070</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.04801.029</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Nunnari</surname><given-names>Jodi</given-names></name><role>Reviewing editor</role><aff><institution>University of California, Davis</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see <ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/review-process">review process</ext-link>). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.</p></boxed-text><p>Thank you for sending your work entitled “Activation of VDAC2 regulates mitochondrial Ca2+ uptake and cardiac rhythmicity” for consideration at <italic>eLife</italic>. Your article has been favorably evaluated by Vivek Malhotra (Senior editor), a Reviewing editor, and 2 reviewers.</p><p>The following individuals responsible for the peer review of your submission have agreed to reveal their identity: Jodi Nunnari (Reviewing editor); Rosario Rizzuto (peer reviewer 1). Reviewer 2 remains anonymous.</p><p>The Reviewing editor and the reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission. All agree that the work is of high quality and represents a significant advance in our understanding of the role of VDAC in calcium handling and cardiac physiology. A majority of the comments pasted below can be addressed by a careful revision of the manuscript. However, as pointed out by reviewer 2, the experiments do not adequately test the authors' conclusion that Ca2+ is directly transferred between the ER and mitochondria. Additional experimentation, for example examining the effect of addition of a Ca2+ chelator.</p><p><italic>Reviewer #1</italic>:</p><p>The authors point to mitochondrial Ca2+ buffering as a protective mechanism against erratic electrical activity, and indicates a prominent role of VDAC2 as a “facilitator” of Ca2+ transfer through MCU channels. In this respect, the authors could consider investigating whether additional, possibly isoform-specific mechanisms add to the role of VDAC2 in Ca2+ permeation across the outer mitochondrial membrane.</p><p>1) Does VDAC 2 interact with MCU and/or with some of its regulators (MICU1/2/3, EMRE or MCUR1)?</p><p>2) Is the expression of MCU and its regulators (“MCU complex”) altered in the tre mutants?</p><p>3) Does pharmacological or molecular stimulation of VDAC2 affect the expression of the MCU complex?</p><p><italic>Reviewer #2</italic>:</p><p>The manuscript reports exciting results but needs to be improved in the following ways:</p><p>1) The results in <xref ref-type="fig" rid="fig3">Figure 3F</xref> show a sample of the identification of one VDAC peptide. The mass numbers are not visible and the color code of red and blue is not clear at all especially the blue. The reader is asked to trust the authors and that is not acceptable. If space is a problem then a clear figure should be added to the supplemental file. Further, the authors report the peptides identified that are a match to VDAC 2 but they do not report what peptides were detected that did not match. What fraction of the peptides matched to VDAC2? There is an unfortunate history of attributing action to VDAC that was not due to VDAC and of identifying VDAC as a binding site when another protein was responsible. This manuscript provides other evidence that supports the conclusion that VDAC2 is the target but that does not excuse the failure to honestly report on other proteins present.</p><p>2) The authors state “... efsevin restores rhythmic cardiac contraction in tre by potentiating VDAC2 activity.” The authors do not measure VDAC2 activity and thus this conclusion is unnecessary speculation. VDAC2 is not an enzyme and thus its action is not so easily defined in this context. The first part of the last sentence on that page is the appropriate summarizing statement.</p><p>3) The authors state: “VDAC is an abundant channel located on the outer mitochondrial membrane serving as a primary passageway for metabolites and ions including Ca2+ (<xref ref-type="fig" rid="fig5">Fig.5A</xref>) (<xref ref-type="bibr" rid="bib44">Rapizzi et al., 2002</xref>; 162 <xref ref-type="bibr" rid="bib2">Bathori et al., 2006</xref>; <xref ref-type="bibr" rid="bib53">Shoshan-Barmatz et al., 2010</xref>).“ The authors fail to point out that it is the closed state of VDAC that favors Ca++ flux. That seminal publication was not cited. (Biochim Biophys Acta. 2007 Oct;1768(10):2510-5.) The state of VDAC2 as well as its presence is critical.</p><p>4) <xref ref-type="fig" rid="fig5">Figure 5</xref> presents some very interesting findings but experimental details are sometimes missing and unclear. In the methods section it talks about perfusion whereas in the figure legend it is called superfusion. It is my understanding that the Fluorostar plate reader does not have perfusion capabilities but rather has the ability to make fluid additions while recording. Is that what was done? Also in the methods section it does not specify the total amount of Ca++ present in the solution, just the presumably calculated free Ca++ concentration. The actual amount of calcium present should be stated and whether the free Ca++ concentration reported is a calculated value of a measured value. Either way it is unclear why the reported value is an exact value. Is this a guess, an approximation?</p><p>In addition, the authors state “We examined whether Ca2+ released from intracellular stores could be directly transported into mitochondria through VDAC2 and whether this process could be modulated by efsevin...” The experiments reported do not distinguish between Ca++ release into the medium and quickly taken up my mitochondria or Ca++ directly traveling between the ER and the mitochondria. That could have been tested in 3C by having a strong chelator in the medium. Thus, with the current data the authors cannot claim evidence for direct transfer. They can claim a more effective uptake of Ca++ into mitochondria after efsevin treatment.</p><p>Based on the results reported in 5B, the authors conclude that Ca++ has been transported into mitochondria in the permeabilized cells, ignoring the ER. The choice of Rhod2 was presumably based on its affinity for Ca++ and its likely saturation with Ca++ in the ER, so that observed changes are likely due to the mitochondria. The authors make no effort to point this out to the reader. It should be addressed.</p><p>5) In the conclusions the authors state: “In this model, VDAC-dependent Ca2+ uptake controls the duration and the diffusion of cytosolic Ca2+ near the Ca2+ release sites...” How, physically, can VDAC control the “duration of cytosolic Ca++” and the “diffusion of cytosolic Ca++”? VDAC cannot control diffusion nor can it control the duration of diffusion. What I hope the authors want to say is that VDAC2 facilitates Ca++ uptake via MCU thus reducing the local Ca++ concentration more rapidly than otherwise.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.04801.030</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p>We appreciate the reviewers’ insightful and constructive suggestions to help us improve our manuscript. We have taken the reviewers’ advice and revised the manuscript accordingly. In addition to clarifying the text, we revised <xref ref-type="fig" rid="fig3">Figure 3</xref>, present new data in <xref ref-type="fig" rid="fig7">Figure 7</xref>, and added three supplementary figures. Below, we address each reviewer’s critiques specifically.</p><p><italic>Reviewer #1 questioned whether the expression of MCU complex would be affected by NCX1 mutation or by the molecular stimulation of VDAC2</italic>.</p><p>We address this question by in situ hybridization. We find that the expression levels of MCU and MICU1 are comparable between wild type and <italic>tremblor</italic> hearts with and without efsevin treatment. These findings are presented in <xref ref-type="fig" rid="fig7s1">Figure 7– figure supplement 1</xref>.</p><p><italic>Reviewer#1 also questioned whether VDAC2 interacts with MCU and its regulators</italic>.</p><p>Our data that restoration of rhythmic contractions in <italic>tremblor</italic> requires the activity of both VDAC2 and MCU provides genetic evidence supporting a functional interaction between VDAC2 and MCU (<xref ref-type="fig" rid="fig7">Figure 7B-D</xref>). As the reviewer pointed out, mitochondrial Ca<sup>2+</sup> transport involves MCU and its regulators. Our model would predict that manipulating the activity of other components of the MCU complex would affect the rescue effect of VDAC2 overexpression. In this revised manuscript, we provide new data showing that: 1) MICU1 is expressed in the developing heart (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), 2) overexpression of MICU1 restores rhythmic contractions in <italic>tremblor</italic> and this effect requires functional VDAC2 (<xref ref-type="fig" rid="fig7">Figure7E</xref>), and 3) there is a synergistic effect of VDAC2 and MICU1 overexpression (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). These findings provide evidence to support the genetic interaction between VDAC2 and the MCU complex and strengthen our hypothesis that mitochondrial Ca<sup>2+</sup> buffering is beneficial to maintain cardiac rhythmicity. Future studies on the biochemical interaction between these proteins would provide further mechanistic insights.</p><p><italic>Reviewer #2 made a few suggestions to</italic> <xref ref-type="fig" rid="fig3"><italic>Figure 3</italic></xref>:</p><p><italic>The reviewer thought that the sample Mass Spec image presented in</italic> <xref ref-type="fig" rid="fig3"><italic>Figure 3F</italic></xref> <italic>was too small for inspection, and questioned the identities of peptides detected in our Mass Spec analysis</italic>.</p><p>We thank the reviewer for pointing out this problem. In the original <xref ref-type="fig" rid="fig3">Figure 3F</xref>, we presented the sample Mass Spec image in the top panel and indicated eight peptides that match VDAC2 in the lower panel. In this revised manuscript, we rearranged <xref ref-type="fig" rid="fig3">Figure 3</xref> as suggested; we present peptide identity in new <xref ref-type="fig" rid="fig3">Figure 3F</xref> and provide an enlarged Mass Spec image in <xref ref-type="fig" rid="fig3s1">Figure 3–figure supplement 1</xref>.</p><p><italic>The reviewer also questioned whether we identified any other proteins interacting with efsevin</italic>.</p><p>In the course of our study, we inspected six sets of data. VDAC2 was the only protein that was not present in the controls but was consistently identified from the efsevin affinity column. Vitellogenin 1 (vtg1) and NADPH quinine 1 (nqo1) were frequently found in both the control and efsevin affinity columns and thus were considered as contaminants. More importantly, our genetic analysis showed that overexpression of VDAC2 recapitulates the rescue effect of efsevin on <italic>tremblor</italic> and knocking down VDAC2 abolishes the responsiveness of <italic>tremblor</italic> to efsevin. Together, these findings support VDAC2 as a target of efsevin.</p><p><italic>Reviewer #2 raised a few questions regarding the mitochondrial Ca</italic><sup><italic>2+</italic></sup> <italic>uptake analyses</italic>.</p><p><italic>The reviewer questioned the experimental detail about the mitochondrial Ca</italic><sup><italic>2+</italic></sup> <italic>uptake experiment in HeLa cells</italic>.</p><p>We apologize for the confusing description. In this experiment, we added Ca<sup>2+</sup> into the samples to make the final Ca<sup>2+</sup> concentration as approximately 10 μM. We have now clarified this information in the Methods and Figure Legend.</p><p><italic>The reviewer thought it would be helpful to point out how Rhod2 functions as a mitochondrial Ca</italic><sup><italic>2+</italic></sup> <italic>indicator</italic>.</p><p>We appreciate the reviewer’s concern and include this information in the Methods section.</p><p><italic>The reviewer thought that “examine whether Ca</italic><sup><italic>2+</italic></sup> <italic>released from intracellular stores could be ‘locally’ transported into mitochondria through VDAC2” would be a better description of our analysis</italic>.</p><p>We thank the reviewer for the suggestion. We have revised the manuscript accordingly. In addition, we provide new data to support a local IP3R-mitochondrial Ca<sup>2+</sup> transfer through VDAC2 (<xref ref-type="fig" rid="fig5s1">Figure 5–figure supplement 1</xref>). Previous reports have provided multiple lines of evidence in various cell types to support local Ca<sup>2+</sup> transfer between IP3 receptors and mitochondria. A commonly used approach is that while both IP3-mediated and SERCA inhibition-induced discharge of the ER Ca<sup>2+</sup> store cause similar global cytoplasmic [Ca<sup>2+</sup>] signal, only the IP3-induced Ca<sup>2+</sup> release is rapidly propagated to the mitochondria (<xref ref-type="bibr" rid="bib46">Rizzuto et al. 1994</xref>, Hajnoczky et al. 1995). We now present a similar experiment with V1/V3DKO MEFs to specifically support local Ca<sup>2+</sup> delivery from IP3 receptors to VDAC2/mitochondria (<xref ref-type="fig" rid="fig5s1">Figure 5–figure supplement 1</xref>).</p><p><italic>Finally, Reviewer #2 made a few editorial suggestions (points 2, 3, 5)</italic>.</p><p>We thank the reviewer for the suggestions. We have revised the manuscript accordingly.</p></body></sub-article></article>